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ABSTRACT 
 The projects described in this dissertation revolve around the functional 
consequences experienced by the transport protein for the neurotransmitter 
dopamine resulting from alterations to its palmitoylation condition or exposure to 
Parkinson disease-inducing transport substrates. This membrane-resident 
transport protein, pragmatically termed the dopamine transporter, relocates 
dopamine from extracellular areas of receptor sites of action to intracellular 
sequestration; the dopamine transporter is a powerful mediator of dopamine 
signaling. As such, genetic, toxicant, or chronic breakdown of dopamine 
transporter function is associated with multiple psychological abnormalities. 
Biomedical research has produced several pharmacotherapies for maladies like 
depression, attention deficit/hyperactivity disorder, and addiction, some of which 
produce their therapeutic profiles by modulating dopamine transporter function. 
The potential for pharmacological manipulation of the dopamine transporter is, 
however, not without its dark side. Dopamine’s critical role in the 
neurotransmission of reward and pleasure render the dopamine transporter a 
favorite target of illicit, addictive drugs of abuse like cocaine and several flavors of 
amphetamine. All of these factors make intimate understanding of the many 
mechanisms involved in the dopamine transporter’s function relevant not only to 
mental, but also societal health. This dissertation explores aspects of dopamine 
transporter mechanistic regulation which, once more thoroughly understood, may 
xix 
be modified to allow finer control over transporter operation, generating novel 
approaches to mental health treatment.  
 The first study investigates site identification and functional 
characterization of post-translational modification of the dopamine transporter by 
a lipid moiety, palmitic acid. Palmitic acid, hexadecanoic acid in IUPAC 
nomenclature, is a saturated 16 carbon fatty acid whose attachment to proteins is 
termed S-palmitoylation. This lipidation process is executed by an array of 
enzymes belonging to the acyl transferase class of the gene name zDHHC. 
Importantly, S-palmitoylation is reversible: a protein’s palmitoylation status can 
change in response to cell stimuli or the palmitoylated protein’s activation. As 
palmitate is of an aliphatic nature, its attachment creates a hydrophobic protein 
microenvironment around the site of its augmentation which propitiates its insertion 
into likewise hydrophobic loci – usually membranes – which induces a protein-
specific functional outcome. A combination of dopamine transporter proteolysis, 
site-directed mutagenesis, acyl-biotinyl exchange, surface biotinylation, and 
forward and reverse dopamine transport assays implicate two N-terminal cysteine 
residues as sites of palmitate incorporation, in addition to the previously analyzed 
C-terminal site, and reveal a role for this lipid modification in dopamine transporter-
mediated dopamine efflux. 
The second project seeks to further understand the dopamine transporter’s 
contribution to Parkinson disease. The hallmark of this disease is a loss of motor 
coordination precipitated by selective death of nigro-striatal dopamine neurons and 
concomitant depletion of dopamine neurotransmission in the movement planning 
xx 
and execution region of the brain – the striatum. The selective loss of these 
neurons directly correlates with dopamine transporter expression; indeed, even 
amongst dopamine neuronal pathways, the nigro-striatal fiber, which is lost to the 
greatest extent of these, has the highest transporter expression. It is for this reason 
the dopamine transporter has been a focus of Parkinson disease research. This 
study utilizes the dopamine transporter substrates 6-hydroxydopamine and 1-
methyl-4-phenylpyridinium, which induce cell death through a panoply of 
biochemical mechanisms and are used to generate Parkinsonian symptoms in 
animal models, to probe for aberrant dopamine transporter function and post-
translational modification. This inquiry revealed that, though these compounds 
induce cell death through similar mechanisms, their dopamine transporter-specific 
effects are quite different. Interestingly, 1-methyl-4-phenylpyridinim is a strong 
inducer of dopamine uptake downregulation and dopamine efflux, a phenomenon 
now implicated in Parkinson disease onset, while 6-hydroxydopamine mitigates 
this efflux event as well as attenuates transporter phosphorylation. 
Overall, this dissertation argues for the existence of N-terminal 
palmitoylation of the dopamine transporter, that palmitoylation is an additional 
contributor to the dopamine efflux paradigm, that transporter-mediated efflux may 
contribute to Parkinson disease onset, and that some of the transporter-specific 
effects of 6-hydroxydopamine may be exploited to alleviate neuropsychiatric 
maladies associated with aberrant dopamine efflux.
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CHAPTER 1 
INTRODUCTION 
Dopamine 
 Preface – The Modern Soma 
 In the ancient Vedic religious text, Rig Veda, is described a deity who is 
both deity and ritual – the immortal and the means of immortality – Soma1. One 
seeking interlocution with the Soma entity ingests the Soma plant or Soma plant 
liquid extract during the ‘Soma-sacrifice’ ceremony to achieve the desired 
transcendence1. The psychotropic ambrosia derived from this god/plant/libation 
induces stimulant, hedonic, hallucinogenic, entactogenic, and euphoric 
experiences and is thought to grant the participant longevity, vitality, and 
resurrection2. The identity of the Soma plant described in the 9th Mandala of the 
Rig Veda has long been a subject of scholarly debate3–5, yet over the epochs a 
multitude of vines, herbs, and flowers has likely been used in the Soma ritual as 
all the plants in question contain mind-altering compounds like ibogaine, L-DOPA, 
ephedrine, tryptamines, or monoamine oxidase inhibitors6. The altar is erected, the 
fire kindled, the Soma berries crushed, the celebrant exults.  
Is this not, in some sense, the experience of the drug abuser? Is he not after 
some form of transcendence? Some attempt, albeit misguided, to escape the 
banality and disappointment of everyday life? Are there more innocuous 
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manifestations of this practice? What of the avid social media user who seeks but 
is, for some reason, unable to find what he is searching for after the hours of 
mindless scrolling? Is it the same exhilaration sensed at the first like of his first post 
he seeks? Or, perhaps, is it the perpetual self-affirmation attained from those 
glimpses into a former lover’s socially sanitized, filtered, and photo shopped faux 
reality where she is still unable to hide those acne blemishes? For what is the 
television watcher searching during the hours of mass consumption of vicarious 
experience through his favorite streaming television dispensary? Happiness? 
Maybe sought after but never achieved. Enlightenment? Surely not. What of 
sports? What, exactly, is the function of ESPN? What of E! Entertainment 
Television? How many human lifetimes are obliterated in trivialities and vacuous 
curiosity? How much ingenuity, innovation, and intellectual and scientific 
breakthrough have been expunged by visions of Harry Potter, Mickey Mouse, and 
Michael Jordan? Television programming, indeed. What about the individual 
overcome by ubiquitous hyper-sexualization and his concomitant descent into 
depths of deviance and diminishing returns associated with sex addiction? Is the 
purpose of his existence achievement of sexual gratification? Of course not, but 
why does his brain insist it is so? How much culpability lies at the feet of society 
and circumstance and how much at his? Or the chronic eater-of-feelings whose 
brain is now wired to interpret that dust sprinkled dehydrated cardboard as food 
but is completely oblivious that it is that very dust doing the wiring and the 
dehydrated cardboard is anything but food?  
How does a civilization’s art degenerate from Franz Schubert to Cardi B?  
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Aldous Huxley was a preeminent philosopher, author, and scientist of his 
generation. In his most famous, far ahead of its time, and prophetic work, Brave 
New World7, Huxley details life in a future totalitarian technocracy which maintains 
absolute control through advanced social, psychological, and biological 
engineering which aims to keep all citizens distracted and contented. This control 
technique is typified in use by all citizens, regardless of socio-economic status, of 
the perfect drug: Soma. It is described7: 
“Two thousand pharmacologists and bio-chemists were 
subsidized in A.P. 178… Six years later it was being produced 
commercially. The perfect drug… Euphoric, narcotic, pleasantly 
hallucinant… Take a holiday from reality whenever you like, and come 
back without so much as a headache or a mythology… One cubic 
centimetre cures ten gloomy sentiments… Now-such is progress-the 
old men work, the old men copulate, the old men have no time, no 
leisure from pleasure, not a moment to sit down and think- or if ever 
by some unlucky chance such a crevice of time should yawn in the 
solid substance of their distractions, there is always soma, delicious 
soma.”    
 
This Soma is consumed to eschew concern, negative emotion, cognitive 
dissonance, and especially sentiments of rebellion and change. How does one 
think, let alone imagine, beyond a matrix of inculcated pleasure-seeking? If one is 
contented and saturated with creature comforts will he be able to break his 
pleasure-inducing fetters? Is there any similitude between Huxley’s dystopian drug 
use and a phenomenon of the modern lifestyle? It seems so: drugs of abuse8–12, 
sex13–17, food18–21, video games22, television23, and social media24, all elicit 
dopamine-potentiated rewarding properties and are capable of producing 
addiction25–32 – a prime mover of which is dopamine (DA) neurotransmission33–35. 
Activation of the DA reward pathway has achieved a coup d’état of motivation for 
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human behavior, or, more likely, a coup d’état of the DA reward pathway has 
achieved dominion over human behavior. This is the modern Soma and it is of the 
Brave New World category rather than the transcendent Vedic form. The former 
produces somnolence while the latter is an attempted step in the journey for truth. 
 The sociological and anthropological impact of dopamine reward seeking 
behavior is utterly mind-boggling. There are not many greater influences on human 
behavior (perhaps money or religion) and the pleasure principle as the end to 
which behavior is directed will increase in influence as newer thrill-inducing 
technologies captivate wider swaths of youth and adult populations (television to 
video games to virtual reality to what?). So, how has the archetypical instantiations 
represented by Cardi B come to predominate over the Franz Schuberts? The 
former is saturated with several forms of sensual appeal to the so called ‘reptilian’ 
brain and directs the mind’s eye toward immediate gratification (pleasure) in place 
of future rewards of greater purpose to which the latter harkens. The net result of 
choosing more and more of the ‘Cardi Bs’ across all sensory input manifestations 
(TV, food, sex, etc.) is the detachment of purposeful action from the reward 
satiation, producing rampant inaction; the release of dopamine-directed reward as 
an end in and of itself. It keeps the user plumbed into the La-Z-Boy rather than 
working to effect change and producing some good in the ‘real world’ and certainly 
not questioning anything. And with the stunning array of new gadgets, toys, 
movies, media platforms, pornography, bands, TV shows, video games, ‘news’ 
programs, sporting events, etc., etc., one ends up floundering in a Pavlovian-
Skinnerian abyss of highly personalized dopamine-guided behavioral patterns. 
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When one gets a tattoo of the DA molecule, is he truly aware of how he is branding 
himself? How has this come to be?   
Pavlov, Skinner, Learning, Behavior, and… Advertising? 
 Reinforcement learning36 (RL) is a process by which learned behavior is 
either supported (positive reinforcement) or opposed (negative reinforcement) by 
environmental stimuli. Pavlovian conditioning (RL)37 occurs when an 
unconditioned stimulus (US), classically a food reward, is predicted by a 
conditioned stimulus (CS), classically a ringing bell, which produces a conditioned 
response (CR), classically salivation, after repeated CS-US trials. This type of RL 
conditions reflexive or involuntary behaviors. The Skinnerian36 advancement of 
Pavlov’s paradigm was to induce a subject’s voluntary behavior in eliciting reward 
or avoiding noxious stimuli. In this paradigm, the experimental subject operates on 
its environment (hence ‘operant’ conditioning) such that a behavior, like lever 
pressing (the lever being the environmental stimulus which cues the behavior), 
produces a food reward, which, after repetition, becomes a behavior-reinforcing 
stimulus pairing. The subject learns that lever pressing produces the food reward. 
Thus, behavior can be conditioned through stimulus-response learning and a 
subject’s voluntary and involuntary behavior can be conditioned to attain reward 
and avert punishment through environmental stimuli (Figure 1).    
 The neurobiological mechanism by which RL occurs is activation of DA 
neurons38,39. The primary neuronal DA tract activated by rewarding stimuli is the 
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Figure 1. Pavlovian and Skinnerian conditioning compared. Simple 
schematic comparison of classical conditioning of a dog’s conditioned 
involuntary response (panting, excitement, tail wagging) to the conditioned 
stimulus (whistle) in expectation of a unconditioned stimulus (food reward) to 
operant conditioning of a mouse’s voluntary response (operation of the lever) 
to elicit the behavior reinforcing food reward. Image courtesy of 
https://fthmb.tqn.com/eKmmGPsmUZvy7k68o36Lq1LUeHg=/1500x1000/filter
s:fill(ABEAC3,1)/2794861-classical-vs-operant-conditioning-
5afc42a343a10300370da76f.png, with permission. 
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mesolimbic DA pathway whose nexus is the ventral tegmental area (VTA) and 
which ultimately innervates the nucleus accumbens (NAc) of the ventral 
striatum40,41 (Figure 2). Rewarding stimuli activate phasic DAergic neuron 
responses42 while punishments actually inhibit their firing43,44. Amazingly, after 
conditioning by Pavlov’s system, activation of these DA neurons transfers from the 
reception of the US to the presentation of the CS45. This process occurs through 
DA coding of prediction error (PE) and determination of incentive salience. A PE 
occurs when an individual’s subjective estimation about a future outcome is 
incorrect, resulting in an outcome that is either greater than anticipated (positive 
PE) or worse than expected (negative PE)46,47 (Figure 3). In fact, the amount of 
excited quantal DA release is directly proportional to the subject’s prediction of the 
reward value48,49 and probability of receiving the reward50. As more and more 
stimulus-response iterations are experienced and their respective values are 
coded for by DA NAc neurons, the stimulus which is associated with the greatest 
DA release will achieve incentive salience, or the highest motivational value, to 
which end the subject’s behavior becomes directed51–53. Indeed, NAc DAergic 
signals are essential for the attribution of incentive salience (‘wanting’), but is not 
required for the hedonic impact of reward (‘liking’)34,54,55, which is mediated through 
opioid56,57 and endocannabinoid58 accumbens transmission. 
 Though it is the primary neurological system for RL59, the DA-mediated 
attribution of incentive salience becomes more complex and individualized in 
higher order species, with, quite obviously, humans being the most complex and  
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Figure 2. Major dopamine pathways in the brain. Schematic diagram of the 
brain’s DA tracts. The nigrostriatal pathway originates in the substantia nigra 
and innervates the striatum and coordinates movement (discussed in greater 
detail in chapter III). The mesolimbic fiber runs from the VTA to the NAc and is 
involved in reward. The mesocoritcal tract also begins in the VTA and 
terminates in multiple regions of the prefrontal cortex and contributes to 
cognitive control and emotion. The tuberoinfundibular pathway cell bodies 
reside in the hypothalamus and send processes to the pituitary gland where DA 
secretion controls prolactin release. Image courtesy of 
http://medlibes.com/uploads/Screen%20shot%202010-07-
15%20at%2010.48.11%20PM.png, with permission.  
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Figure 3. Firing of 
DA neurons 
encodes reward 
prediction error. 
Reception of an 
unexpected 
rewarding stimulus 
induces burst firing of 
DA neurons, positive 
prediction error (top). 
Application of a 
conditioned stimulus 
induces phasic 
neuron stimulation, 
but the reception of 
the reward does not 
alter basal DA neuron 
firing pattern, no 
prediction error 
(middle). Conditioned 
stimulus induces 
expected neuronal 
excitation, but the 
absence of reward 
ablates even tonic 
firing of DA neurons, 
negative prediction 
error (bottom). 
Adapted from ref #46, 
with permission. 
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individualized. Perturbations in attribution of incentive salience are associated with 
two prevalent human diseases: depression can be a result of deficits of incentive 
salience attribution wherein the depressed individual assigns subnormal 
motivational value to rewarding tasks60–62, and addiction coincides with excessive 
attribution of incentive salience to behavior which negatively affects one’s life, 
producing chronic alterations to DA-mediated motivation systems63,64. It is the 
usurpation of the DA-incentive salience system that results in addiction65, yet it is 
also a takeover of this mechanism which marketing and advertising is hoping to 
achieve – with every advertisement, all the time. The advertiser’s tactics are 
sometimes subtle66–68 and sometimes overt (Figure 4)69,70, but the end result is a 
ruthless, shameless attempt to subvert the target audience’s (you) incentive 
salience attribution capacity – to instill, using an amalgamation of Skinnerian and 
Pavlovian RL schemas71, irrational desire for a product one does not need, and, 
ultimately, to habituate the purchase and use of the marketed product72. Thus an 
effective advertisement (like the one in Figure 4) supplies the CS that stimulates 
involuntary NAc DA signaling (the strength of which depends on the amount and 
subjective significance of pleasure modalities it appeals to) in the viewer’s brain 
which alters his perception of the product (reality, really) such that he values the 
product higher than what it is actually worth, generating an illogical desire for its 
attainment. Advertising contributes to several addiction-associated disorders 
including alcoholism73, compulsive buying74, and obesity75–77. We learn by the 
modern soma, we survive by the modern soma, we behave according to the   
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Figure 4. How does this sell bacon cheeseburgers?!? This conditioned 
stimulus (advertisement) appeals to multiple aspects of male psychology, 
producing a manipulated DAergic reaction which biases the inflicted individual’s 
attribution of incentive salience and subsequent behavior toward ingestion of 
Carl’s Jr. rather than Burger King (probably) because….sex. What a time to be 
alive!! 
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modern soma, but we do not thrive on the modern soma. The ubiquity of DA 
science extends from pharmacological through the sociological disciplines, and, 
after analysis of our epoch by scholars of millennia to come, it will be of 
anthropological and historical significance. 
Synthesis, Exocytotic Release, and Receptors 
In the central nervous system, DA executes numerous physiological 
functions. In addition to the previously described learning and rewarding properties 
of DA neurotransmission, emotion, cognition, movement, memory, and sensory 
processes all involve DA signaling. Intriguingly, DA has been demonstrated to 
perform peripheral functions as well: DA is synthesized and secreted by pancreatic 
β-cells whereby it regulates insulin release78–80, and it is likewise produced and 
released by immune cells to modulate several aspects of their function, including 
cytokine synthesis and secretion81–83. DA is a catecholamine transmitter which 
relates that its structure possesses a benzene ring from which project two hydroxyl 
functional groups and ethylamine (Chapter 3 Figure 1). DA is synthesized from its 
amino acid precursor L-Tyrosine (Tyr) which is transported across the blood brain 
barrier (BBB) by large neutral amino acid transporter (LAT1)84 and enters DA 
neurons. The sequential enzymatic reactions of tyrosine hydroxylase (TH) and 
aromatic L-amino acid decarboxylase (AADC) cooperate to produce DA from Tyr. 
TH requires tetrahydrobiopterin, iron (Fe2+) and molecular oxygen to catalyze the 
rate-limiting step of DA synthesis to further hydroxylate Tyr’s aromatic ring. The 
molecular product of this reaction is L-dihydroxyphenylalanine (L-DOPA) which, 
like Tyr, passes the BBB via LAT1 activity84 and is therefore a standard treatment 
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for the DA-deficient disorder, Parkinson disease (PD)85. TH function is increased 
by neuron depolarization-induced extracellular signal-regulated protein kinase 
(ERK) and cAMP-dependent protein kinase (PKA) phosphorylation of Serine (Ser) 
residues 19, 31, and 4086,87. AADC removes the carboxylic acid moiety from L-
DOPA’s α-carbon, creating 3,4-dihydroxyphenethylamine or dopamine (DA). DA 
can be converted to norepinephrine by dopamine beta hydroxylase which can be 
further modified to epinephrine by phenylethanolamine-N-methyltransferase in 
neurons expressing these enzymes88. Cytosolic DA is tightly controlled as it can 
transform into cytotoxic reactive oxygen species and is thus rapidly deaminated by 
monoamine oxidase enzymes or methylated by catechol-o-methyl transferase89.  
After synthesis, DA is sequestered into vesicles through the vesicular 
membrane transport protein, vesicular monoamine transporter (VMAT2)90 (Figure 
5). VMAT2 packages DA into vesicles in opposition to the DA concentration 
gradient through its pairing with proton antiport congruent with the H+ gradient. Low 
vesicular pH is maintained by vesicular H+-ATPase activity. Once loaded with 
transmitter, vesicles undergo anterograde trafficking along microtubule filaments 
by ATP-dependent kinesin function91,92. Once docked in the axon terminal ‘active 
zone’, priming of the vesicle, fusion of the vesicular and plasma membranes, and 
egress of the vesicle cargo is carried out by soluble N-ethylmaleimide sensitive 
factor attachment protein receptor (SNARE) machinery93–95 (Figure 6). SNARE 
proteins belong to two broad categories: vesicle (v)-SNAREs which are present on 
granule membranes, and target (t)-SNAREs which reside in the nerve terminal 
plasma membrane. Conformational adjustment of the α-helical t-SNARE syntaxin 
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Figure 5. Synthesis and release of DA. DA is enzymatically generated from 
L-tyrosine by sequential tyrosine hydroxylase and aromatic L-amino acid 
decarboxylase activities. DA is translocated into vesicles through vesicular 
monoamine transporter. DA is released into the synapse after vesicular fusion 
with the axon terminal membrane. Excess cytosolic DA is catabolized by 
monoamine oxidase in neurons and catechol-o-methyltransferase in 
surrounding cells. Image reproduced from 
https://i.pinimg.com/originals/6d/6b/60/6d6b60d62d807a077c7327bd177b216
e.jpg, with permission. 
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Figure 6. Protein mechanisms in vesicular-plasma membrane fusion 
and pore formation. A-B) Syntaxin conformation change recruits SNAP 
interaction. C-E) VAMP proteins (synaptotagmin, synaptobrevin) interact 
with the q-SNARE system which, with the aid of CA2+ forms a cis-SNARE 
complex which fuses the plasma and vesicle membranes. F-G) SNAP 
and NSF proteins sequentially bind to the SNARE structure. ATP 
hydrolysis mediated by NSF induces conformational changes to the NSF 
structure which produces spring-loaded disassembly of all involved 
protein complexes. Imaged adapted from ref # 93, with permission.    
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causes its HaHbHc domain to move away from its glutamine rich region which 
recruits assembly of other t-SNARE α-helical proteins, such as SNAP-25. This t-
SNARE complex interacts with the likewise α-helical v-SNARE proteins, 
synaptobrevin and synaptotagmin (Syt), forming a cis-SNARE complex. After 
action potential-stimulated Ca2+ influx and Ca2+-Syt binding, this cis-SNARE 
structure acts like a zipper to draw the vesicular and plasma membranes together 
and provide the energy necessary for membrane fusion and pore formation93,96,97. 
Additional SNAP proteins and the N-ethylmaleimide sensitive factor (NSF)-
ATPase congeal to form a SNAP/SNARE/NSF 20s complex98. NSF-catalyzed ATP 
hydrolysis disassembles the 20s and cis-SNARE structures99,100.  
DA exocytosis occurs through this pore. Only 25-40%101,102 of the estimated 
33,000103 vesicular DA molecules are released upon fusion events which allows 
the neuron to more finely control transmitter release and avoid arduous vesicle 
recycling tasks101. Once released into the synapse, DA interacts with its 
endogenous cognate receptors to produce DA’s physiological outcomes. These 
DA receptors are of 5 separate classes, all of which are members of the GPCR 
superfamily and therefore have an extracellular amino-terminus, cytosolic 
carboxyl-terminus, and seven α-helical transmembrane (TM) domains104. 
Conventionally, the DA receptor subclasses are divided according to their 
modulation of cAMP production: D1 and D5 receptors are coupled to the adenylate 
cyclase (AC)-stimulating G-protein, Gαs/olf, while D2, D3, and D4 receptor subtypes 
signal through Gαi/0 to inhibit AC activity; D1-type receptors stimulate protein kinase 
A (PKA) while D2-type receptors blunt PKA (Figure 7). An important assimilation 
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point for dopamine receptor signaling is dopamine and cAMP regulated 
phosphoprotein, Mr 32 kDa (DARPP-32). PKA phosphorylates DARPP-32 at 
Thr34, turning DARPP-32 into a potent inhibitor of protein phosphatase 1 which, 
in turn, influences a plethora of cellular systems105,106. DARPP-32 mediates the 
activity of several drugs of abuse that affect DAergic neurotransmission107,108. It is 
now known that in addition to these canonical cAMP-PKA pathways, DA receptors 
signal through several cAMP-independent mechanisms including but not limited 
to: transactivation of multiple receptor tyrosine kinases109–111; interaction with and 
modulation of N-type calcium channel112,113 and Na+/K+ ATPase114,115 operations; 
stimulation of phospholipase C116,117 through Gβγ118 and Gαq119,120 mechanisms; 
coupling to β-arrestin, classically associated with receptor desensitization121, to 
form scaffolds122 for kinase and phosphatase signaling processes123; and signaling 
through protein kinase B to prompt glycogen synthase kinase activity124–126. DA 
receptors are functionally regulated through post-translational phosphorylation127–
131 and palmitoylation132–138. After DA is released into the synapse to signal through 
its target receptors, its concentration and duration in the synaptic schism is 
terminated through reuptake into the presynaptic neuron via the dopamine 
transporter.         
The Dopamine Transporter 
 Structure and Mechanism of DA Transport 
 The dopamine transporter (DAT)139 is the an integral membrane protein 
found predominantly in the perisynaptic membranes of presynaptic DA nerve 
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Figure 7. Dopamine receptor effector proteins and signaling cascades. 
Schematic representation of DA signaling through its cognate receptors. D1 and 
D5 receptors excite AC function through Gαs/olf; D2, D3, and D4 subtypes 
attenuate AC production of cAMP by Gαi. cAMP stimulates PKA which 
phosphorylates numerous downstream targets, like DARPP-32, and influences 
several signaling pathways and transcription factors. DA receptors have also 
been shown to activate PLC through Gαq and Gβγ proteins. Image adapted from 
https://medicine1journal.wordpress.com/2013/08/15/congestive-heart-failure-
pharmacological-approach-iii/ with permission. 
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terminals and is so named for its function: transport of DA from the synaptic space 
to the cytosol of the presynaptic neuron. After regulated control of vesicular DA 
egress, DAT is the primary means of controlling DA homeostasis in the synapse; 
thus, it regulates DA’s influence on target pre- and post-synaptic neurons. DAT 
belongs to the solute carrier family 6 (SLC6)140 gene family which also includes 
neurotransmitter and amino acid transporters for serotonin (5-HT), Norepinephrine 
(NE), γ-aminobutyric acid (GABA), and glycine, proline, taurine, and the osmolytes 
betaine and creatine with whom DAT shares high amino acid sequence homology 
and structural topology139,141–143. Advancement in understanding the secondary 
structure of the neurotransmitter sodium symporters (NSSs; transporters DAT, 
SERT, NET) coincided with their molecular cloning144–147 and subsequent 
hydropathy146,147 and topology148–150 assessments which deduced 12 α-helical 
transmembrane (TM) domains, cytosolic N- and C- termini, a large, glycosylated 
extracellular loop (EL) structure between α-helices III and IV, and a disulfide 
bond151 within this EL (Figure 8)152. The NSSs possess approximately 600 amino 
acids; the rat DAT (rDAT) isoform contains 619 residues, and the human (hDAT) 
consists of 620. It wasn’t until the resolved X-ray crystal structure of the NSS 
bacterial homologue leucine transporter (LeuT) that the tertiary structure of the 
SLC6 family came into view142. LeuT, like the predicted NSS secondary structure, 
comprises 12 α-helical TM domains and intracellular N- and C- termini. The LeuT 
crystal also revealed unwound regions in TMs 1 and 6 which coordinate substrate 
binding142,153, and a pseudo-symmetric inverted repeat structure wherein TMs 1-5 
form a V-shape motif which is mirrored by similar, but inverted architecture of TMs 
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Figure 8. Secondary structure of DAT based on the LeuT crystal 
structure. Schematic representation of DAT topology. Relative position of 
DAT’s 12 TM domains are shown with unwound regions as the putative 
site of substrate and Na+ ion binding. Also shown are the intracellular 
amino and carboxyl termini and glycosylation events on EL 2. Image 
adapted from ref # 152, with permission.   
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6-10142. This ‘5 + 5 inverted repeat’ motif has since been discovered in transporters 
unrelated to members of the SLC6 family or LeuT154. 
The drosophila melanogaster (d)DAT crystal structure was resolved in 2013 
and provided further insight into DAT architecture (Figure 9)155. DAT core tertiary 
structure is similar to LeuT in that TMs 1-5 and 6-10 form a 5 + 5 inverted repeat 
fold inside of which TMs 1, 3, 6, 8, and 10 form a substrate permeation pathway. 
This DAT crystal does, however, have several unique features. TM 12 has a kink 
induced by a proline residue halfway along its α-helix which causes the portion in 
the cytoplasmic plasma membrane leaflet to jut-out from the transporter. A 
cholesterol molecule is wedged between TMs 1a, 5, and 7 which likely helps 
maintain DAT in an outward-open structural conformation156 as it inhibits free 
motion of TM 1a as DAT progresses through substrate bound and unbound 
conformations157, though this cholesterol might be an artifact of the crystallization 
process. The intracellular C-terminus is composed of a 2.5 turn helix and acts as 
a latch through interaction with intracellular loop (IL) 1 which may play a role in 
substrate transport155.  
DAT-mediated DA translocation is conducted in an alternating access 
mechanism (Figure 10)158. This process involves movement of the transporter 
through multiple conformations initiated by substrate binding to an outward-open 
conformation159,160. This outward-open conformation exposes the substrate 
binding site to the extracellular solvent. After DA enters its binding pocket, Asp79 
being crucial for coordination of DA’s amine group161,162, the transporter transitions 
22 
 
  
Figure 9. X-ray crystal structure of dDAT. Tertiary structure of dDAT 
locked in the outward-open conformation by the tricyclic antidepressant 
nortriptyline. Displayed are the locations of the 12 TM α-helical barrels, the 
cytoplasmic cap produced by the C-terminal peptide which contains a short 
helical segment (blue), the bend to TM 12 produced by Pro572 tilting TM 
12b away from the permeation core (purple), and a cholesterol molecule 
(yellow) bound between TMs 1a, 5 and 7 where it reduces the ability of TM 
1a to isomerize between its conformational states necessary for substrate 
translocation. Image adapted from ref # 155, with permission.   
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into an occluded position in which neither extracellular nor intracellular substrate-
solvent exposure occurs via movement of TMs 1b, 6a, and EL4 into the substrate 
binding vestibule, forming an extracellular ‘gate’ which seals the substrate pocket 
from the extracellular milieu142,157,163. The final transition from this occluded state 
to the inward-open, substrate-releasing conformation is induced by movement of 
TM 1a away from DAT’s core164 and breaking of the intracellular gating network 
which is comprised of a salt bridge between Arg60 and Asp436 stabilized by 
cation-π stacking of Arg60 and Tyr335165,166, and latching mechanisms formed by 
TM1a-IL1-C-terminus interactions155. After DA is released into the cytosol, DAT 
isomerizes back into the outward-open conformation for further DA translocation 
events. 
DAT is a secondary active transporter and as such the motive power for 
‘uphill’ DA transport is supplied by movement of sodium ions down its Na+/K+-
ATPase-maintained concentration gradient, like other members of the NSS 
family167. DAT’s substrate transport process involves simultaneous transport of 
DA, two Na+ ions and one Cl- ion; DAT is, therefore, a symporter. The first Na+ ion 
(Na1) stabilizes the outward-open conformation until substrate binding, and 
accommodates DA binding and DAT conformational transitions during transport 
rearrangements; it is coordinated by the side-chains of dDAT residues Asn49, 
Ser320, and Asn352 and backbone carbonyls of Ala44 and Ser320 from TMs 1 
and 6155,168–170. The second Na+ ion’s (Na2) location is accommodated by residues 
from TMs 1 and 8 by peptide carbonyls from Gly42, Val45, and Leu417 and side-
chain oxygens of Ser421 and Asp420; this Na+ ion also stabilizes the outward-
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open pre-substrate DAT structure, controls cation permeation of DAT, and its 
release into the cytosol triggers conformational isomerization to the inward-open 
pose155,169–172. The Cl- ion resides 5 Å away from the Na1 location and is 
coordinated by Tyr69, Gln316, Ser320, and Ser356 from TMs 2, 6, and 7; the Cl- 
molecule increases affinity for Na+ at the Na2 site and thus regulates inward-open 
conformation probability155,172,173. The alternating access conformational pivots 
occur only after the DA substrate binds to an outward-open conformation primed 
by two Na+ and one Cl- co-substrates. Once DA binds, TMs 1b and 6a, with EL4, 
form a ‘lid’ which seals off access to extracellular solvent. The intracellular segment 
of TM 5 unwinds, granting cytosolic solvent access to the Na2 site. This event 
sparks the ultimate transition of DAT to its inward-open conformation which sees 
TM1a swing away from the substrate binding pocket producing solvation thereof 
and the concomitant entry of DA and the Na2 sodium into the neuronal cytosol 
(Figure 11)171,174,175.  
 Regulation 
 DAT function is subject to extensive control through posttranslational 
modification and biding partner interactions. Rat and human DATs are 
glycosylated on Asn residues of EL2176. This modification supports DA uptake 
Vmax, trafficking of the transporter to the plasma membrane and its retention there, 
and decreases potency of cocaine177–179. Increased DAT glycosylation has been 
proposed as a mechanism which increases susceptibility to DA neuron loss 
  
25 
 
Figure 10. Alternating access mechanism of substrate transport. The 
substrate binding vestibule is exposed to extracellular solvent in the outward-
open pose (left). After substrate binds in the permeation core, the transport 
protein undergoes structural rearrangements to restrict extracellular solvent 
access (top). This involves TMs 1b, 6a, and EL4 in the LeuT transport process. 
This occluded conformation is relieved by rearrangement of intracellular gating 
and loop networks and involves ‘swinging out’ of TM 1a which exposes the 
substrate binding locus to intracellular solvent into which substrate is released 
– this is the inward-open conformation (right). The transporter then moves back 
through the occluded pose to return to the outward-open conformation. Adapted 
from ref # 158, with permission.   
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Figure 11. Na+ Involvement in the neurotransmitter transport process. Na+ 
ions (green spheres) enter into their Na1 and Na2 sites and stabilize the 
outward-open transporter conformation (1) which allows substrate to bind and 
induce isomerization to the occluded formation (2). This induces closer of the 
extracellular vestibule, causing TM 5i to unwind (3) and provide intracellular 
access to Na2, releasing this Na+ (4). TM 1a shifts away from the protein 
allowing substrate and Na+ from Na1 to enter the cytosol (5) after which the 
transporter returns to the outward-open conformation (6). Image adapted from 
ref # 175, with permission.   
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characteristic of Parkinson’s disease by increasing DAT plasma membrane 
expression180.The E3 ubiquitin ligases Nedd 4-2 and Parkin catalyze ubiquitylation 
of DAT on N-terminal Lys residues 19, 27 (hDAT), and 35 which contributes to 
PKC-stimulated DAT endocytosis and degradation181–183. Parkin function has been 
demonstrated to support DAT function as mutant Parkin proteins, which result in 
PD, fail to properly ubiquitylate improperly folded transporters184. Cholesterol 
likewise aids in DAT activity as removal of this molecule results in reduced DA 
transport Vmax, increased Km, loss of outward-open conformational stabilization, 
Amphetamine (AMPH)-stimulated DA reverse transport (efflux), and leads to 
aberrant PKC-induced downregulation156,185–187. This cholesterol-DAT interplay 
contributes to DAT association with cholesterol-rich lipid raft membrane 
microdomains where scaffolding of DAT-involved signaling complexes is 
accomplished186. 
 Membrane raft and non-raft DAT networks with multiple protein partners. 
The Ras-like GTPase in neurons, Rin, interacts with DAT’s C-terminus to control 
endocytic processes after PKC activation188. Similarly, Flotillin-1-DAT interplay 
contributes to transporter internalization as well as raft recruitment and AMPH-
induced DA efflux189. The SNARE protein Syntaxin 1a (Syn1a), along with the 
receptor for activated C kinase (RACK), complex with DAT to induce its 
internalization through phosphorylation by PKC190. Syn1a interacts with the N-
terminus of DAT by which it also blunts DA uptake, reduces transporter plasma 
membrane expression, and supports AMPH-stimulated DA reverse transport191–
193. The Lewy body aggregate protein, α-Synuclein, binds to DAT’s distal C-
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terminus where it enhances DA efflux, blunts DA uptake, and increases DAT-
membrane raft localization194–196. The G-protein βγ subunits physically interact 
with the cytosolic carboxyl-peptide of DAT to promote DA efflux and blunt 
uptake197–199.  The D2 DA autoreceptor partners with the DAT at its distal N-
terminus to promote DAT recycling to the surface and acutely increase DA 
reuptake through PKC and extracellular signal regulated kinase (ERK)-related 
mechanisms, an operation that may be perturbed in Schizophrenia200–203 (Figure 
12).  
Perhaps the most studied of DAT’s regulatory processes is 
phosphorylation204. Kinase-potentiated phosphorylation events have been 
demonstrated to exert functional control over DAT. Activation of PKC induces 
reduced DA transport Vmax, enhances DA efflux parameters, and plays a role in 
DAT internalization205. PKC activators like phorbol 12-myristate, 13-acetate (PMA) 
and agonists for receptors coupled to Gαq stimulate transporter 32P 
incorporation206,207. Opposite of the PKC effect, ERK activity increases DAT 
plasma membrane expression and DA uptake capacity201,208. Calcium-calmodulin 
dependent kinase II (CAMKII) interacts with DAT C-terminally and contributes to 
in vivo and heterologously expressed AMPH-induced, DAT-mediated DA efflux, 
but has only been shown to phosphorylate a DAT N-terminal peptide in vitro209–211. 
PKA upregulates DAT function212. DAT surface expression and function is 
increased by tyrosine kinase activity213, and insulin receptor-coupled Akt2214 and 
PI3K215 activities maintain DAT surface levels. Okadaic acid inhibition of their 
function revealed the protein phosphatases 1 and 2a (PP1 and PP2a) act upon 
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Figure 12. DAT binding partner interactions. Schematic representation of the 
relative locations of DAT protein interactors and posttranslational modifications. 
Pictured are the known ubiquitination, phosphorylation, and palmitoylation sites 
(discussed later) as well as the interacting proteins Flotillin-1, α-synuclein, Rin, 
Parkin, D2 DA receptor, and Syn1a. Image adapted from ref # 227, with 
permission.  
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DAT to control basal transporter phosphorylation levels207, and of these, PP1 
predominates216,217, though a direct protein-protein interaction has been 
established between DAT and PP2A218.  
 Phosphoamino acid analysis of DAT-32PO4+ radiolabeling demonstrated 
around 90% of the tracer’s incorporation occurred on Ser residues while the 
residual incorporation occurred on Thr residues, with the majority of this labeling 
happening on the distal N-terminus of DAT219. Ser2, Ser4, Ser7, Ser12, and Ser13 
reside in a PKC consensus domain, and truncation of this peptide eliminates the 
bulk of basal and stimulated 32PO4 radiolabeling206,220. Individual Ser to Ala 
mutations fail to eliminate transporter 32PO4 incorporation, indicating multiple 
phosphorylation events occur at DAT’s N-terminus. In vitro phosphorylation of the 
recombinant rDAT N-terminus (NDAT) was induced by PKC at Ser4, Ser7, and 
Ser13, and CAMKII phosphorylated Ser13 and PKA catalyzed phosphorylation of 
Ser7216. Ser7 phosphorylation has been identified on the hDAT isoform by mass 
spectrometry and this event contributes to conformational equilibrium221. ERK-
catalyzed, proline-directed phosphorylation of rDAT Thr53 has likewise been 
demonstrated by mass spectrometry and requires peptide backbone isomerization 
by the prolyl isomerase PIN1 for dephosphorylation216,222,223. This residue supports 
both DA uptake and AMPH-stimulated reverse transport, and its phosphorylation 
is stimulated by amphetamines216,223,224. DAT phosphorylation site information is 
summarized in Figure 13.  
 
31 
 
  
 
 
Figure 13. Phosphorylation of the dopamine transporter. Schematic 
diagram of rDAT phosphorylation sites. The majority of DAT phosphorylation 
occurs on the cytoplasmic rDAT N-terminus. Known phosphorylation sites, 
Ser7, Ser13, and Thr53 are represented by larger blue circles. Potential Thr 
and Ser phosphorylation sites are shown in purple. Other PKC Domain 
residues are blue, residues of the CAMKII binding domain are green, and 
Pro residues surrounding the proline-directed phosphorylation site, Thr53, 
are yellow. Enzymes involved in each phosphorylation event are indicated 
by solid arrows, and dashed arrows represent AMPH and PKC contribution 
to each event. The orange Cys residue is the known rDAT palmitoylation 
(red) site. Adapted from ref  #204, with permission.   
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DAT-Mediated DA Efflux 
In addition to synaptic clearance of DA, an important physiological event 
likewise mediated by DAT is non-vesicular release of DA, commonly known as DA 
efflux. This effect is reliably induced by amphetamines and is, along with 
competitive inhibition of DAT-coordinated reuptake of DA169,225, responsible for the 
pharmacological and rewarding properties of AMPH and amphetamine-like 
compounds226. Multiple hDAT single nucleotide polymorphisms are unstimulated 
hyper-releasers of DA, a phenotype termed anomalous DA efflux (ADE), and this 
characteristic is thought to contribute to disease etiology227. Several cellular and 
DAT-centered mechanisms have been identified to produce DA efflux. N-terminal 
phosphorylation of DAT is necessary for AMPH-induced DA efflux228, a process 
which involves PKC and CAMKII activity204,229–231. This amino-terminus forms 
electrostatic interactions with PIP2-enriched membranes through distal Lys 
residues to propitiate DA efflux232. AMPH generates a channel-like conformation 
of DAT through which quantal-like DA efflux occurs233; additionally, this channel 
conformation is able to depolarize the neuron234 which draws Na+ and Ca2+ into 
the cell235 further exciting DA release phenomena236,237. DA redistribution from 
vesicles by AMPH action at VMAT2 increases the cytosolic efflux-ready DA 
concentration238–240. Methamphetamine (METH) produces efflux in many of the 
same ways as AMPH but an additional sigma receptor functionality has been 
demonstrated to contribute to METH-induction of DA reverse transport241,242. 
 DAT Disease Association 
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 Because DA signaling is vital to many important neurological processes, 
maintenance of its normal transmission, a process to which proper DAT function 
is necessary, is paramount for sound mental health. As such aberrant DAT 
processes have been implicated in addiction, ADHD, and PD243. The DAT-
targeting psychostimulants cocaine,  AMPH, and ecstasy (MDMA) increase DA 
neurotransmission through inhibition of DA reuptake by DAT blockade (cocaine) 
or substrate properties characteristic of competition for the DAT substrate binding 
pocket and induction of reverse DA transport (AMPH, MDMA)244,245; thus, as they 
greatly increase DA signaling in the mesocorticolimbic areas of the brain, they are 
highly addictive substances246. Chronic use of these compounds begets altered 
DA neuron synaptic connections and DAT surface expression247–250 which implies 
drug taking (or drug taking-like behaviors) can induce neurobiological changes that 
hamper the addict’s reward computation, incentive salience attribution, and 
behavioral habits53,63,72. 
 PD results from loss of substantia nigra DA neurons which precipitates 
dysfunction of coordinated movement. The DAT substrates 6-hydroxydopamine 
and 1-methyl-4-phenylpyridinium are extensively used in laboratory settings to 
reproduce loss of the nigrostriatal fiber to recapitulate characteristics of this 
disease; thus, DAT has long been hypothesized to play a role in PD 
pathology251,252. While the majority of PD cases are of unknown origin, genetic 
mutations to α-synuclein and the E3 ubiquitin ligase Parkin, both DAT-interacting 
proteins, are causative of two familial types of PD253. DAT mutations which 
severely reduce levels of mature transporter and significantly reduce DA uptake 
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capacity have been found in patients with infantile parkinsonism-dystonia152,254,255, 
and an individual with comorbid early-onset PD and ADHD was discovered to have 
multiple DAT amino acid polymorphisms which significantly blunt DA reuptake and 
induce an ADE phenotype256. These findings suggest a role for aberrant DAT 
forward and reverse transport characteristics in PD etiology.     
 Because attention and cognition are DA signaling-moderated processes257, 
malfunctioning DAT has been hypothesized to contribute to ADHD etiology258,259. 
Indeed, the primary pharmacotherapies for ADHD are DAT-modulating 
compounds; AMPH and methylphenidate, which operates akin to cocaine, act to 
relieve the DAergic imbalance attributed to ADHD260–262. Multiple hDAT missense 
mutations have been discovered in diagnosed individuals263,264. These rare 
polymorphisms produce the amino acid substitutions Val55Ala, Arg237Gln, 
Ile312Phe, Val382Ala, Asp421Asn, Ala559Val, and Arg615Cys (Figure 14)227,265. 
Val55Ala, Ile312Phe, Val382Ala, and Asp421Asn display reduced DA uptake 
capacity265,266, and the Arg615Cys substitution generates AMPH-insensitivity, 
reduced membrane micro domain targeting, and is constitutively recycled267. The 
best-studied of these is Ala559Val. This hDAT polymorphism displays altered 
trafficking and lateral membrane mobility, elevated tonic phosphorylation of its N-
terminus, and an ADE phenotype which is blocked by AMPH and dependent upon 
D2 DA receptors and CAMKII activity268–271. In addition, our lab has demonstrated 
Ala559Val hDAT to be palmitoylation deficient (Shetty et al. unpublished study).   
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Figure 14. 2D topological diagram of location of hDAT coding variants. 
Yellow circles represent the relative locations of genetically produced 
transporter amino acid substitutions. Ala559 resides in the exofacial barrel of 
TM12 in a hydrophobic pocket generated by two Trp residues. This pocket is 
likely disrupted by the bulkier Val side chain which may alter TM12, and as a 
result, overall DAT conformation. Adapted from ref #227, with permission. 
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S-Palmitoylation 
 Overview 
S-acylation (also known as S-palmitoylation) is the chemical reaction of a 
fatty acid (predominantly palmitate) to a target protein via enzymatic attachment of 
the acid locus to the objective protein’s available cysteine sulfhydryl side chain, 
producing a thioester bond (Figure 15)272. This attachment is unlike other protein 
lapidating events (N-myristoylation, o-acylation, prenylation), which produce stable 
covalent bonds, in that it is reversible273. This provides opportunity for the cell to 
control a protein’s palmitoylation state in response to dynamic cell signaling274. The 
cell generates entire enzyme systems to catalyze protein S-acylation and 
deacylation: protein S-acyltransferases (PATs), also known as DHHC enzymes 
(DHHCs) for the presence of a conserved Asp-His-His-Cys motif at their catalytic 
domains, produces the sulfhydryl-lipid bond on the target protein, and acyl protein 
thioesterases (APTs) and protein palmitoyl thioesterases (PPTs) are the primary 
palmitate-removing enzymes275–277. In humans, the DHHC family of enzymes is 
comprised of 23 different genes of the name zDHHC for their conserved zinc finger 
Cys rich domain and DHHC tetrapeptide regions278. Structurally, these enzymes 
possess four to six TM domains and, based on the recent crystal structure of 
human zDHHC20, adopt a teepee-like conformation with the top just protruding 
into the luminal/extracellular space and the catalytic DHHC active site residing at 
the cytosol-membrane interface (Figure 16)279. An important feature of this 
structure is the hydrophobic cavity that spans the active site well into the plasma 
membrane; this cavity is crucial for housing the acyl group and confers acyl chain  
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Figure 15. Mechanism of protein S-palmitoylation. Schematic diagram of 
the S-palmitoylation reaction. The fatty acid from an acyl-CoA molecule is 
covalently bound to an acceptor protein sulfhydryl to form a thioester bond. This 
reaction is catalyzed by DHHC enzymes. The opposite reaction is catalyzed by 
APTs or PPTs to produce both a free fatty acid and sulfhydryl group. Image 
adapted from ref # 272, with permission.  
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Figure 16. Structure of human DHHC20. hDHHC20 has four TM domains 
(green), a cytosolic Cys-rich domain (blue) which contains the catalytic DHHC 
motif and coordinates two Zn2+ ions and is comprised of multiple β-sheets and 
α-helices, and a C-terminal domain which provides additional contacts with the 
membrane through its hydrophobic residues. Adapted from ref #279, with 
permission.  
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length acceptance specificity of each DHHC279,280. DHHC PATs operate by a ping-
pong mechanism where the first step is an auto-acylation event followed by 
transfer of the acyl group to the substrate protein281, and are themselves regulated 
by palmitoylation of Cys residues outside their catalytic domains282. There are two 
APT and one active PPT enzymes which belong to the metabolic serine hydrolase 
superfamily, APT1, APT2, and PPT1277,283. The APT enzymes catalyze the 
depalmitoylation of cytosolic palmitoyl-proteins and themselves undergo 
palmitoylation to shuttle between golgi, mitochondrial, and plasma membranes284–
286. PPT1 depalmitoylates degrading proteins in the lysosome and experiences 
dynamic palmitoylation cycling to reach the lysosomal membrane287–290. More 
recently the α/β-hydrolase domain containing protein 17 (ABHD17) family was 
likewise demonstrated to catalyze depalmitoylating episodes, specifically of N-ras, 
PSD-95, and microtubule-associated protein 6291–293. Though the depalmitoylases 
demonstrate some substrate specificity, the relative dearth of enzymes which 
perform this function indicates these enzymes have high substrate promiscuity or 
the existence of as of yet undiscovered deacylating proteins272,277.  
Once attached, the fatty acid confers local hydrophobicity to its substrate 
peptide to produce divers, protein-specific, functional outcomes (Figure 17)294: 
targeting of cytosolic proteins to plasma or organelle membranes295–298; 
myristylated or farnesylated proteins can undergo palmitoylation to reinforce 
membrane binding properties in a process known as kinetic trapping299–301; S-
acylation contributes to protein assembly and exit from endoplasmic reticulum or 
40 
 
  
 
 
Figure 17. Functional consequences of protein palmitoylation. Schematic 
diagram of some protein-specific palmitoylation outcomes. Protein S-acylation 
can exert control over protein trafficking, aggregation, degradation, assembly, 
and/or oligomerization. Adapted from ref #294, with permission.  
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Golgi apparatus302; it can produce protein aggregation and oligomerization303,304; 
it increases its target protein’s stability305–307; endosomal and lysosomal trafficking 
which controls protein recycling or degradation290; protein membrane microdomain 
affinity changes with S-acylation occurrence308,309; and S-acylation is able to 
relieve TM domains of hydrophobic mismatch310. From this it follows that the 
concert of S-acylation events in a cell at any given time regulate a wide variety of 
cellular processes, and, extrapolating further, organ function. The biological 
functions palmitoylation influences includes cell signaling311, exocytosis312, 
endocytosis313,314, metabolism315,316, immune system signaling317,318, ion 
conductance319–323, and a deluge of host-pathogen interactions324–329. One can see 
further evidence for this in the ever-expanding array of diseases linked to aberrant 
S-acylation of important proteins330. Neuronal ceroid lipofuscinosis290,304,331,  
multiple cancers332, Huntington’s disease303,333,334, schizophrenia335,336, 
inflammation337, and more278,338. This hitherto underappreciated post-translational 
modification has been calculated to be the fifth most abundant human post-
translational modification with approximately 1000 proteins demonstrated to be 
palmitoylated to date339,340. 
The Acyl-Biotinyl Exchange Assay 
Acyl-biotinyl exchange (ABE) (Figure 18)341 is the primary method used in 
these studies to investigate palmitoylation aspects of DAT’s nature. This technique 
involves three basic steps: (1) blocking of non-acylated Cys thiol groups with N-
ethylmaleimide or methyl methanethiosulfonate; (2) specific chemical cleavage of 
thioester bonds at neutral pH with hydroxylamine; (3) biotinylation of post-  
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Figure 18. The ABE method. Outline of the major steps of the ABE technique. 
Free thiols are blocked by the MMTS reagent after which the sample is split into 
two. One half undergoes hydroxylamine cleaveage of the thioester bond freeing 
a Cys sulfhydryl group while the other half is treated with Tris buffer which does 
not chemically remove palmitate from Cys thiols. A sulfhydryl-specific 
biotinylation reagent accesses the once-palmitoylated thiol, and biotinylated 
proteins are captured via avidin affinity chromatography. This capture does not 
occur in the Tris-treated sample. Peptides are eluted and are free for detection 
by SDS-PAGE and Western blotting or mass spectrometry. 
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palmitoylated sulfhydryl groups with thiol-reactive biotinylation reagents and 
subsequent NeutrAvidin affinity chromatography isolation. The strength of this 
assay is that it is Cys-centered. This allows for perhaps greater sensitivity than 
radiolabel procedures as protein-palmitate bonds are chemically severed, free 
palmitate is removed, and the label is applied whereas radiolabeling requires 
endogenous removal of unlabeled fatty acid and incorporation of the radiotracer342. 
This technique labels the entire cellular volume of palmitoylated proteins and, 
consequently, is easily adapted to mass spectrometry proteomic techniques330,343. 
DAT Palmitoylation 
 rDAT and hDAT isoforms have been demonstrated to be palmitoylated in 
rat brain tissue and heterologous expression systems by both metabolic 
incorporation of [3H]palmitic acid and ABE techniques344. Incorporation of the 
[3H]fatty acid occurs rapidly with its detection at 1 hour, indicative of rapid tonic 
cycling of this modification of DAT. The irreversible PAT inhibitor, 2-
bromopalmitate (2BP), significantly attenuates DAT palmitoylation indicating DAT 
palmitoylation is catalyzed by DHHCs. Acute 2BP treatment of rat striatal 
synaptosomes produced significant reduction in DA uptake Vmax, while extended 
2BP treatment times of DAT-expressing cells produces loss of full length DAT 
protein and low Mr DAT fragments344. These two findings indicate palmitoylation 
sustains acute DA uptake capacity and chronic control over DAT degradation. DAT 
is acylated by DHHCs 2, 3, 8, 15, and 17345. Co-expression of these PATs and 
rDAT produce significantly increased DA uptake and total DAT expression. Rat 
DAT possesses five cytoplasmic Cys residues predicted to be exposed to the 
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aqueous environment and available for S-palmitoylation. Cys6, Cys135, Cys341, 
Cys522, and Cys580 were mutated to Ala and assayed for any palmitoylation loss 
by [3H]palmitic acid metabolic incorporation. Cys580Ala radiolabeling was reduced 
by ~50% relative to WT while the others induced no change. This result indicates 
Cys580 is a primary site of DAT palmitoylation (Figure 19, top)344,346. Cys580 
resides at the cytoplasmic interface of TM12 and likely contributes to the proper 
architecture of that α-helix, perhaps aiding its kink155. Cys580Ala rDAT displays 
attenuated DA uptake kinetics and an increased turnover rate, indicating Cys580 
modification is crucial for DA uptake capacity and DAT stability345,347. Our work has 
also demonstrated DAT phosphorylation and palmitoylation mechanisms 
reciprocally control each other347. Pharmacological positive or negative 
manipulation, or mutational ablation of known sites, of each modification produced 
the opposite effect on the corresponding modification. Thus, mutation of the known 
DAT PKC phosphorylation site, Ser7, induced increased transporter 
palmitoylation, and the Cys580Ala substitution increased DAT phosphorylation. 
Likewise, PKC activation decreased DAT palmitoylation, PKC inhibition increased 
DAT palmitoylation, 2BP treatment increased DAT phosphorylation, and DHHC2 
overexpression decreased DAT phosphorylation (Figure 19, bottom)346,347. That 
~50% of the [3H]palmitate remains on Cys580Ala rDAT likely means incorporation 
is occurring at other site(s) (probably Cys6, Cys135, Cys 341, and/or Cys 522) 
undetectable by this technique which have yet to be elucidated. Mutagenesis of 
other sites may induce higher tonic palmitoylation of transporter populations still 
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Figure 19. Dopamine transporter palmitoylation mechanisms. Top Schematic 
topological diagram of relative locations of potential DAT palmitoylation sites (orange 
circles) and known palmitoylation site, Cys580 (orange circle with attached red 
cylinder). Bottom DAT functional characteristics altered by its palmitoylation cycle. 
DAT palmitoylation increases DA uptake Vmax and DAT stability while opposing DAT 
phosphorylation. Adapted from ref #346, with permission. 
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possessing Cys580. We therefore implemented alternate strategies, beginning 
with ABE analysis of intracellular Cys to Ala mutations, to resolve other DAT 
palmitoylation sites from background that cannot be detected by the radiolabeling 
technique.    
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CHAPTER 2 
DAT N-TERMINAL PALMITOYLATION AND THIS MODIFICATION’S EFFECT 
ON DOPAMINE EFFLUX 
Abstract 
 The dopamine transporter (DAT) is the dopaminergic neuron plasma 
membrane transport protein responsible for recollection of synaptic dopamine (DA) 
into the neuron after stimuli-induced transmitter release. DA signaling is 
responsible for a panoply of physiological consequences, and, as the primary 
conduit for DA entry into eponymous neurons, DAT is one of the most popular 
targets of legal and illegal chemical agents aiming to modulate DA signaling. 
Malfunctioning DATs are thought to contribute to a host of neurological maladies 
including bi-polar disorder, attention deficit/hyperactivity disorder (ADHD), 
addiction, and Parkinson disease. DAT operation is precisely controlled through 
protein interactors and post-translational modifications including phosphorylation, 
glycosylation, ubiquitination, and, of importance here, S-palmitoylation – the labile, 
enzymatic union of cysteine sulfhydryl moieties with the fatty acid palmitate via a 
thioester linkage. S-palmitoylation conveys protein-specific functions which can 
include protein oligomerization, membrane micro domain localization, protein 
maturation, and alleviating transmembrane domain hydrophobic mismatch. DAT 
palmitoylation was previously discovered at rat (r)DAT Cys580 and modification of 
this residue acutely increases DA uptake Vmax without altering DAT surface 
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expression and opposes long-term DAT degradation. As the enzymatic processes 
of S-palmitoylation is primarily thought to occur on intracellularly accessible 
cysteines, Cys to Ala mutants of each intracellular rDAT cysteine residue (6, 135, 
341, 522, and 580) were assessed for its S-palmitoylation phenotype by the acyl-
biotinyl exchange (ABE) method. This process revealed an ~50% loss of 
palmitoylation detection in the Cys580Ala mutant alone, a result almost identical 
to the previous study utilizing incorporation of radiolabeled fatty acid. The 
remaining radiolabel and ABE signals imply the presence of one or more 
palmitoylation sites undetectable by these protocols. Subsequently, the alternate 
sites of rDAT S-palmitoylation were probed by utilizing a combination of multiple-
site Cys to Ala mutagenesis, Asp-N and CNBr proteolytic peptide mapping of 
endogenous and heterologously expressed rDATs in conjunction with ABE 
analyses. These methodologies revealed Cys6 and, surprisingly, the exoplasmic 
Cys90 as the likely secondarily acylated rDAT sites. These residues were then 
assessed for functional relevance by surface biotinylation, DA transport saturation 
analyses, and reverse DA transport (efflux) assays. Palmitoylation of Cys6 residue 
may invoke tethering of the cytosolic NH2-terminus of rDAT to the plasma 
membrane and this Cys residue was shown to support DAT-mediated DA efflux. 
Cys90 acylation may aid DAT endosomal retention and substrate reuptake as the 
Ala90 mutant displays increased surface populations and decreased apparent DA 
affinity. As DAT S-palmitoylation supports forward and reverse transport 
processes, therapeutic alteration of this DAT modification may alleviate DAT-
involved disease burden.    
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Introduction 
 Cognition, movement, fear generalization, reinforcement learning, and, as 
a result, behavior are mammalian functions mediated in the central nervous 
system by the neurotransmitter dopamine (DA)42,65,244,348–350. As DA contributes to 
these vital processes, its maintenance at a proper equilibrium is essential for 
individual health, and divergence from healthy DA homeostasis is hypothesized to 
contribute to the mental disorders attention-deficit/hyperactivity disorder 
(ADHD)351, Parkinson disease352, and schizophrenia353. Licit therapeutic strategies 
target the properties of DA flux262, and abuse of these properties by illicit drug use, 
and even excess video game play22,26, greatly increase the likelihood of addiction 
disorders10. It follows, then, that fine-tuned regulation of synaptic DA concentration 
is essential to well-being. After exocytotic transmitter release, DA signaling is 
primarily controlled through its removal from the perisynaptic space via the 
presynaptic plasmalemmal dopamine transporter (DAT) into the cytoplasm of the 
expressing neuron139. DAT is a member of the sodium and chloride dependent 
solute carrier 6 family of neurotransmitter transporters140 and is the molecular 
target of several therapeutic agents and drugs of abuse which manipulate DAT 
properties to alter synaptic DA concentration354,355.      
 A large body of work has demonstrated DAT function to be precisely 
regulated by trafficking, post translational modification, and binding partner 
mechanisms227, and much of this regulation occurs at DAT’s cytosolic N-terminus. 
Control over DAT endocytosis and lysosomal degradation is exerted by 
ubiquitination of three lysines on DAT’s N-terminus183, a process stimulated by 
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PKC activation182. The human DAT (hDAT) associates with the anionic 
phospholipid phosphatidylinositol (4,5)-bisphosphate (PIP2) through distal N-
terminal lysine residues, which alters hDAT stimulant interaction232.  Several 
proteins bind to N-terminal regions of DAT to modulate DAT function: the DA D2 
autoreceptor binds N-terminally on DAT leading to the recruitment of additional 
DATs to the plasma membrane, increasing DA uptake200; the soluble N-
ethylmaleimide-sensitive factor attachment receptor (SNARE) protein syntaxin 1A 
networks with the first 33 residues of DAT which reduces forward DA transport and 
promotes DA transport (efflux)191,193; and multiple kinases phosphorylate DAT on 
its N-terminus356.  
Striatal rDAT was demonstrated to be phosphorylated on N-terminal 
residues by aminopeptidase instigated loss of [32P]radiolabel219. At the distal N-
terminus resides a protein kinase C (PKC) binding domain. Activation of this kinase 
significantly elevates transporter phosphorylation207,206, blunts DA uptake 
velocity357, redistributes DATs away from the plasma membrane358, and 
phosphorylates an N-terminal DAT peptide (NDAT) at Ser4, Ser7, and Ser13 in 
vitro221. Proline-guided phosphorylation occurs on rNDAT216 through extracellular 
signal-related kinase (ERK) action at rDAT Thr53223; a process which is sensitive 
to psychostimulant activity and supports DA uptake and efflux359. Additionally, the 
human (h)DAT N-terminus undergoes phosphorylation at Ser and Thr residues221 
including Thr48360,361. This N-terminal DAT phosphorylation pattern is essential for 
induction of DA efflux228,362, and pharmacologic activation of DAT-mediated 
reverse transport coincides with phosphorylation of this DAT locus204. 
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Our lab has demonstrated DAT to be lipid-modified through the S-
palmitoylation process344. S-palmitoylation is the enzymatic addition of one of a 
species of long chain saturated fatty acids, predominately palmitate, to sulfhydryl 
functional groups of cysteine residues creating a chemically labile thioester 
bond294. This process is catalyzed by the zDHHC gene family of palmitoyl 
acyltransferases (PATs)278 and reversed by two separate thioesterase families: 
palmitoyl protein thioesterases (PPTs) are lysosomal-resident enzymes which 
hydrolyze fatty acid-protein thioester linkages during protein degradation287; and 
acyl protein thioesterases (APTs) are cytoplasmic thioesterase enzymes363. 
Palmitoylation increases the affinity of lipidated protein micro domains for the 
hydrophobic interior of an intracellular membrane, inducing substrate-subjective 
functional outcomes which can include: localizing the modified protein to a target 
membrane micro domain; trafficking the protein to recycling endosomes or to 
lysosomes; maturation of protein in the endoplasmic reticulum; alleviating 
hydrophobic mismatch of transmembrane α-helical structures; changing the profile 
of protein interactome interactors; and, ultimately, modulation of the function of the 
acylated protein294.  The initial study on rDAT palmitoylation identified Cys580, 
which resides at the cytoplasmic interface of transmembrane domain (TM) 12, as 
the primary DAT palmitoylation site344. Mutation of this Cys residue induced 
fragmentation of the protein, demonstrating acylation of this residue antagonizes 
transporter degradation; additionally, loss of Cys580 palmitoylation suppressed 
DA transport Vmax347.  
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The first report on DAT palmitoylation did not exclude the occurrence of this 
modification on residues other than Cys580344, perhaps due to the limitations of 
the methodology used. More recently, a reciprocal coordination between DAT 
phosphorylation and palmitoylation was discovered to modulate DAT operation347. 
Through mutagenesis and pharmacological means, it was shown that when DAT 
phosphorylation increases palmitoylation decreases; alternatively, when 
phosphorylation decreases palmitoylation increases. The aim of this study was to 
probe for the existence of rDAT palmitoylation sites separate from Cys580 in native 
tissue and heterologous expression systems. We then analyze Ala mutations of 
the novel DAT palmitoylation sites for DA uptake kinetic parameters and assess 
the influence general cellular palmitoylation, and DAT-specific palmitoylation, exert 
over DAT-mediated DA efflux.   
Results 
Acyl-Biotinyl Exchange Analysis of Cys to Ala Point Mutant Palmitoylation   
Our previous study identified Cys580 as a major DAT palmitoylation site 
using metabolic radiolabeling with [3H]palmitate. Our results suggested this 
method may have been inadequate to delineate a second, lower-stoichiometric, 
site if the incorporation of the radiolabeled fatty acid is indistinguishable from 
background labeling. To overcome this potential limitation, we employed the acyl-
biotin exchange (ABE) protocol341 which, due to increased availability of once-
palmitoylated Cys residues via hydroxylamine (NH2OH)-induced liberation of the 
fatty acid from the sulfhydryl functional group of Cys residues, produces higher 
sensitivity342,364. This technique was used to delineate from background the effect 
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of mutational alteration of the five DAT intracellular Cys residues to determine the 
presence of DAT palmitoylation sites in addition to Cys580.   
However, the ABE technique yielded results akin to our previous study 
(Figure 1): Cys580 is the major rDAT palmitoylation site, and removal of this site 
reduces DAT palmitoylation to ~50% (*p<0.05 Cys580 versus WT, n=8), with no 
discernable S-palmitoylation loss associated with Cys to Ala ablation of the other 
potential sites (p>0.05 for Δ21, Cys135Ala, Cys341Ala, and Cys522Ala versus 
WT, n=3 or more independent experiments). These results were nearly identical 
to the radiolabeling study; the incomplete loss of Cys580Ala ABE readout again 
indicates additional palmitoylation events on DAT, but the mutational loss of these 
additional sites may induce over-palmitoylation of Cys580 in these transporter 
populations. 
 Palmitoylation of Single Intracellular Cys rDATs 
To resolve palmitoylation events which may occur at lower stoichiometry 
than Cys580 on WT rDATs, all intracellular Cys residues were mutated to Ala save 
one which was studied for the occurrence of DAT palmitoylation events at that 
particular cysteine via ABE (Figure 2). This methodology revealed Cys6 as a PAT 
substrate as rDAT populations possessing only Cys6 produced significantly 
greater ABE signal above rDATs possessing only intracellular Cys135, Cys341, or 
Cys522 (##p<0.01 Cys6 versus Cys135, Cys341, and Cys522). The Cys6 readout 
was similar to that of rDATs with only Cys580; therefore, this approach confirmed 
Cys580 as a DAT palmitoylation site. Here Cys6, like Cys580, was significantly 
less palmitoylated than WT (***p<0.001 Cys6 versus WT n=8; ***p<0.001 
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Figure 1. Palmitoylation levels of WT and mutant rDATs measured 
by ABE.  Membranes isolated from LLCPK1 cells expressing WT or Cys 
mutant DATs were subjected to ABE to determine palmitoylation levels. 
Upper Panels: ABE DAT levels normalized to Total DAT levels (middle 
panels). Samples were subjected to SDS-PAGE and immunobloting 
using MAb 16. Bottom Panel: Quantification of palmitoylation intensity 
normalized to total DAT levels (means ± SE of 3 or more independent 
experiments). C580A *p < 0.05 relative to WT, ANOVA with Dunnett’s 
post hoc test. These experiments confirm Cys580 as an rDAT 
palmitoylation site but were unable to distinguish any other palmitoylation 
sites of perhaps lesser abundance. 
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Figure 2. ABE analysis of WT and multiple Cys to Ala mutants of rDAT.  
Mutants are named such that the number represents the only cysteine 
remaining on the cytosolic portion of rDAT, e.g. ‘580’ is 
Cys522/341/135/6Ala, leaving only Cys580 available to intracellular S-
palmitoylation. Membranes isolated from LLCPK1 cells expressing the 
indicated DAT were subjected to ABE.  These experiments confirm Cys580 
as an rDAT palmitoylation site and support Cys 6 as an additional site of 
the fatty acid incorporation. n=3 for 522, 341, 135; n=8 for WT, 580, and 6. 
*** p<0.001 for 580 and 6 vs WT, ### p<0.001 for 580 vs 522, 341, 135, and 
##p<0.01 for 6 vs 522, 341, 135 (means ± S.E.). Statistical analyses 
performed by ANOVA with Tukey’s post hoc test. 
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Cys580 versus WT, n=8). That the Cys580 mutant did not possess palmitoylation 
signatures like WT is further evidence supporting the existence of extra-580 
palmitoylation sites; this set of experiments impugns Cys6 as that site. 
 Palmitoylation of DATs with or without the Putative Palmitoylation Sites  
To strengthen this finding, we compared palmitoylation signals of rDAT 
mutants possessing only the two putative palmitoylation sites 
(Cys135/341/522Ala) with an rDAT mutant population possessing the three 
intracellular Cys residues and without the two that are palmitoylated (Cys6/580Ala) 
(Figure 3). The results show palmitoylation of Cys135/341/522Ala to be at WT 
levels (p>0.05 Cys135/341/522Ala versus WT, n=3) while Cys6/580Ala ABE 
signals are at background levels (**p<0.01 Cys6/580Ala versus WT, n=3). This 
further supports Cys 6 as a second rat DAT palmitoylation site.  
 In Vivo Palmitoylation of the rDAT N-terminal Peptide   
To determine if rDAT is palmitoylated on its N-terminus in vivo, an approach 
similar to previous photoaffinity labeling with subsequent proteolytic peptide 
mapping of the transporter was implemented365–368. However, in these 
experiments the photoaffinity tagging was replaced with the ABE process. 
Enzymatic and chemical proteolysis of DATs isolated from rat striatum were 
subjected to the ABE process. The first approach utilized Asp-N; this enzyme 
selectively cleaves peptide bonds on the N-terminal side of aspartic acid residues 
and has been shown to generate a DAT peptide of approximately 19 kDa by  
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[FJ1]  
Figure 3. Palmitoylation analysis of mutant DATs containing only the 
Cys residues suspected of being palmitoylated or containing all Cys 
residues except the suspected palmitoylation sites. Indicated mutants 
were subjected to ABE as described previously. Data are presented as % 
WT control. n=3, 103.90 ± 7.80 p>0.05 for C135/314/522A versus rDATs 
(mean ± S.E.), and ** p<0.05 for C6/580A versus WT (mean ± S.E.). 
Statistical analyses were performed by ANOVA with Tukey’s post hoc test. 
These results further support both Cys580 and Cys6 as palmitoylation sites 
as DATs possessing only these two intracellular Cys residues have WT 
level palmitoylation signatures. 
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ASP-N proteolysis at Asp174, a peptide which is detected by a monoclonal DAT 
antibody against an N-terminal epitope (MAb16)369(Figure 4).  Synaptosomal 
preparations from excised rat striatal tissue were treated with 1µg/mL Asp-N in SP 
buffer for 45 minutes at 25oC (control samples were incubated in SP alone) after 
which the samples underwent the ABE protocol. After isolation, digestion, ABE 
purification, and immunoblot detection with MAb16, a Western blotting signal of 
~19 kDa emerged (Figure 5). This peptide is the N-terminus of rDAT (residues 1-
174) and, because it was isolated by ABE, is modified by S-palmitoylation. This is 
the first demonstration of N-terminal rDAT palmitoylation in vivo. This portion of 
rDAT’s N-terminus contains both Cys135 and Cys6, and the Asp-N-ABE protocol 
is unable to distinguish between S-palmitoylation at Cys6 and Cys135. 
Cyanogen Bromide (CNBr) Digestion and ABE Analysis of the rDAT N-
terminus 
To further delineate if this in vivo N-terminal rDAT palmitoylation event 
occurs at Cys6 or Cys135, CNBr chemical proteolysis with subsequent ABE was 
utilized. CNBr cleaves peptide bonds C-terminally to methionine residues. CNBr 
selectively hydrolyzes DAT proximal to  methionine residues (106, 111, 116) in the 
second transmembrane α-helix, generating a DAT N-terminal peptide of an 
approximate 11 kDa molecular weight366(Figure 6) detectable by MAb16 Western 
blotting. Importantly, this peptide does not include Cys135. Synaptosomes were 
prepared from extracted rat striatum and treated with 100 µL of 70% formic acid 
with or without 1M CNBr for 1 hour at 25oC in the dark followed by ABE analysis  
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Figure 4. Asp-N schematic proteolytic profile of rDAT. Schematic diagram 
of the expanded membrane topology of DAT with 12 TMDs and intracellularly 
facing N- and C-termini. Vertical stacks of amino acids (blue) represent the 12 
α-helical membrane spanning domains. The extracellularly available Asp 
residues are highlighted in mauve. The known sites of glycosylation (black 
branched sticks), phosphorylation within the PKC-domain containing Ser7 (blue 
circle) and relative sites of potential S-palmitoylation (orange circles) are 
shown. The C-terminal helix (yellow, FREKLAYA) is also shown, and is the 
epitope for the C-20 antibody. Asp-N proteolysis of rDAT will generate a 19 kDa 
peptide which can be visualized after immunoblotting with MAb16 and a 36 kDa 
peptide visible after immunoblotting with C-20.  
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Figure 5. Asp-N proteolysis of rat striatal synaptosomes and subsequent 
detection of palmitoylated rDAT N-terminus by ABE.  Synaptosomes were 
isolated from rat striatal brain tissue. Synaptosomes were digested with 1 μg/mL 
Asp-N in SP buffer for 45 minutes at 25oC while control samples were incubated 
in SP alone under otherwise identical conditions. Digested synaptosomes were 
subjected to ABE. SDS-PAGE, and immunoblotting with MAb 16 revealed the 
presence of an ~19 kDa N-terminal palmitoylated fragment. ‘M’ arrow indicates 
mature DAT, and ‘AP’ arrow indicates Asp-N-generated DAT peptide whose 
presence in the NH2OH ABE lane indicates N-terminal DAT palmitoylation. This 
acylation event likely occurs at Cys6 and/or Cys135. This procedure is unable to 
distinguish between these two sites.  
 
M 
AP 
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Figure 6. Depiction of N-terminal rDAT displaying N-terminal 
methionine residues, the primary aspartic acid cleavage site by Asp-
N, and relative locations of intracellular cysteines potentially 
accessible for S-palmitoylation.  Methionine residues are in black. The 
green residues on the N-terminus represent the epitope for anti-rDAT 
primary antibody MAb16. Cleavage with Asp-N at Asp174 (large red 
residue) produces an ~ 19-kDa N-terminal peptide containing the epitope 
for MAb 16, Cys6 and Cys135 as seen in Figure 6. CNBr digestion at 
Mets 106, 111, or 116 in transmembrane domain 2 would generate the 
~11-kDa N-terminal DAT fragment seen in Figure 7. 
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(Figure 7). This experiment demonstrates the N-terminus of DAT remains 
palmitoylated in the absence of Cys135 – implicating Cys6 as the likely site of this 
modification. This, in combination with the preceding findings (Figures 1-3), 
supports Cys6 as an rDAT S-palmitoylation site and likely rules out this event 
occurring at Cys135.   
CNBr Proteolytic Mapping of Cys to Ala rDATs Expressed in LLCPK1 Cells 
To confirm the in vivo proteolytic peptide mapping-ABE results, the same 
set of experiments performed on striatal rDAT were implemented on WT, Cys6Ala, 
and Cys135Ala rDATs. Plasma membrane fractions of LLCPK1 cells stably 
expressing each of the aforementioned DATs were isolated and treated with 1M 
CNBr in 70% formic acid. Control samples were treated with formic acid alone to 
control for fragmentation induced by acid hydrolysis. After 1 hour incubation in the 
dark, the samples were subjected to the ABE process and palmitoylated DAT 
peptides were detected by MAb16 immunoblotting (Figure 8). The ~11 kDa 
palmitoylated DAT peptide presented in both the WT and Cys135Ala rDATs, which 
was expected, but also the Cys6Ala rDATs, which was not anticipated. This result 
suggests either the presence of additional N-terminal palmitoylation events, or 
non-sulfhydryl binding of the sulfhydryl-specific biotinylating reagent. The more 
likely answer is an additional lipidation event, though the only other Cys amino acid 
resident to the N-terminal peptide generated from CNBr chemical fragmentation is 
Cys90, which resides on the extracellular surface of transmembrane domain 1. 
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[FJ3]
Figure 7. CNBr digestion of rat striatal synaptosomes and subsequent 
detection of palmitoylated rDAT N-terminus by ABE. Synaptosomes were 
prepared from extracted rat striatum and treated with 100 µL of 70% formic acid 
with or without 1 M CNBr for 1 hour at 25oC in the dark. Digested synaptosomes 
were then subjected to ABE as described above and palmitoylated peptides 
were detected by SDS-PAGE and immunoblot analysis with Mab 16. ‘M’ arrow 
indicates mature DAT, and ‘CP’ arrow indicates CNBr-generated DAT peptide 
whose presence in the NH2OH ABE lane indicates N-terminal DAT 
palmitoylation, most likely at Cys 6.  
M 
CP 
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Figure 8. CNBr digestion of WT, Cys6Ala, Cys135Ala rDATs in LLCPK1 
cells. LLCPK1 cells stably expressing the indicated rDAT were subjected to 
CNBr chemical fragmentation at a concentration of 1M CNBr in water and 
formic acid (CNBr ‘+’ lanes) or water and formic acid alone (CNBr ‘-‘ lanes) 
for 1 h at ambient temperature in the dark. Reactions were terminated with 
900 μL of water and lyophilized. Final pellets were solubilized in 4SB buffer 
and subjected to ABE analysis and immunoblotting with MAb16. ‘M’ arrow 
indicates mature DAT, and ‘CP’ arrow indicates CNBr-generated DAT 
peptide. Presence of a CP in the C6A lane implies additional N-terminal DAT 
palmitoylation events on this peptide which may occour on the only other 
Cys residue, 90. 
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Analysis of Cys90 Palmitoylation 
 Cys90Ala rDAT cDNA was generated and the protein was transiently 
produced in LLCPK1 cells for assay by ABE (Figure 9). These experiments 
demonstrate Cys90 to undergo S-acylation as the Cys90Ala rDAT ABE signature 
was significantly reduced versus WT (0.96 ± 0.05 versus 1.34 ± 0.13 ABE DAT to 
total DAT ratio,* p<0.05). This is only a modest reduction in palmitoylation, which 
is expected as the palmitoylation substrates Cys580 and Cys6 are still present in 
this DAT population; however, Cys90 may be acylated at higher stoichiometric 
levels than Cys6 as the loss in Cys90Ala palmitoylation is detectable by ABE alone 
while the Cys6Ala loss of palmitoylation is not. This Cys residue is known to be 
highly reactive to MTS reagents370,371 and reactive oxygen species of DA ortho-
quinone372 which alter DA binding properties of DAT. Palmitoylation of Cys90 
would be remarkable for multiple reasons. This result would represent, to our 
knowledge, the first known extracellular palmitoylation event. The application of 
the lipid to Cys90 would likely occur co-translationally in the ER while the majority 
of palmitoylating events occur post-translationally in the Golgi298,373. Though it may 
be reversible, re-palmitoylation likely does not occur once DAT is presented at the 
plasma membrane as the acyltransferase machinery capable of re-applying 
palmitate resides within the cell301.           
 Surface Expression Analysis of Palmitoylation-Deficient rDATs  
The palmitoylation of Cys6 or Cys90 may serve different functions in DAT 
regulation than palmitoylation of Cys580, which, in stably expressing heterologous 
expression systems, supports DA uptake Vmax and opposes DAT  
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Figure 9. Palmitoylation characterization of Cys90Ala rDAT. WT or 
Cys90Ala rDATs were transiently transfected into LLCPK1 cells and ~36 
h later were collected and plasma membrane isolation was performed. 
The samples were then subjected to the ABE protocol and 
palmitoylated DATs were detected by Western blotting with MAb 16. 
0.96 ± 0.05 versus 1.34 ± 0.13 ABE DAT to total DAT ratio,* p<0.05 n=7 
(mean ± S.E.M.) Statistical analyses were performed by Student’s t test. 
This result S-palmitoylation may occur on Cys90. 
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degradation344. To determine the functional outcomes of Cys6 and Cys90 
palmitoylation, Cys6Ala, Cys6/580Ala, and Cys90Ala rDATs were analyzed for 
surface expression and DA uptake saturation kinetics.  
 The Cys580ala stably expressed in LLCPK1 cells displayed acute functional 
alterations which were not precipitated by a loss of plasma membrane 
transporters. Here we tested all the palmitoylation-deficient mutants for differential 
surface expression patterns by cell surface biotinylation analysis after transient 
transfection in LLCPK1 cells (Figure 10). The Cys580Ala rDAT has unaltered 
surface characteristics (Figure 10b) (n=3, 0.94 ± 0.06 versus 1.18 ± 0.14 surface 
to total DAT ratio, p>0.05) compared to WT rDAT. The same holds true for both 
Cys6Ala (Figure 10a) (n=3, 0.96 ± 0.06 versus 1.02 ± 0.04 surface to total DAT 
ratio, p>0.05) and Cys6/580Ala (Figure 10c) (n=7, 1.02 ± 0.03 versus 1.06 ± 0.07 
surface to total DAT ratio, p>0.05); however, the Cys90Ala rDAT (Figure 10d) (n=5, 
1.05 ± 0.03 versus 0.95 ± 0.02 surface to total DAT ratio, *p<0.05) displayed 
elevated surface transporter levels relative to WT rDAT. The increase in surface 
expression may not be due to loss of a lipidating event at Cys90, but rather the 
loss of a reactive Cys. An alternative is the lipidation of Cys90 keeps this population 
of DATs in an endosomal pool where they can be acted upon by PPTs in the event 
increased DA uptake capacity is required by the cell; e.g. post-action potential DA 
exocytosis - the result of the Ala90 rDAT would be less endosomal retention and 
increased plasma membrane transporters. 
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Figure 10. Surface biotinylation analysis of Cys to Ala rDATs’ surface 
expression. WT, Cys6Ala, Cys580Ala, Cys6/580Ala, or Cys90Ala rDAT were 
transiently transfected  in LLCPK1 cells ~36 h prior to surface biotinylation analyses. 
A): Cys6Ala versus WT n=3, 0.96 ± 0.06 versus 1.02 ± 0.04 surface to total DAT 
ratio, p>0.05; B): Cys580Ala versus WT, n=3, 0.94 ± 0.06 versus 1.18 ± 0.14 surface 
to total DAT ratio, p>0.05. C): Cys6/580Ala versus WT, n=7, 1.02 ± 0.03 versus 
1.06 ± 0.07 surface to total DAT ratio, p>0.05. D): Cys90Ala versus WT, n=5, 1.05 
± 0.03 versus 0.95 ± 0.02 surface to total DAT ratio, * p<0.05. (mean ± S.E.M.). 
These results indicate unchanged plasma membrane populations in Cys6Ala, 
Cys580Ala, and Cys6/580Ala populations while mutational lalteration of Cys90 to 
Ala induces increased DAT surface populations. This effect may be due to loss of 
Cys90 palmitoylation.  
 
A) B) 
C) D) 
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DA Uptake Saturation Kinetics of Palmitoylation Deficient rDATs 
 To further examine the functional outcomes that loss of palmitoylation 
confers upon DAT, [3H]DA saturation transport studies were performed on 
Cys6Ala, Cys580Ala, Cys6/580Ala, and Cys90Ala rDATs transiently expressed in 
LLCPK1 cells. Figures 11-14 detail the surface normalized Michelis-Menten 
saturation curves and kinetic parameters (Km and Vmax) reflecting the DA transport 
kinetics of these rDATs. Cys6Ala rDAT (Km = 1.63 ± 0.24 versus 2.09 ± 0.68, 
p>0.05 µM; Vmax = 165.8 ± 7.8 versus 186.7 ± 27.6 pmol/min/mg, p>0.05) (Figure 
11), like Cys6/580Ala rDAT(Km = 2.19 ± 0.14 versus 1.80 ± 0.15 µM, p>0.05; Vmax 
= 137.0 ± 24.4 versus 129.3 ± 19.0 pmol/min/mg, p>0.05) (Figure 13), displays 
unaltered uptake kinetics relative to WT; transiently generated Cys580Ala (Figure 
12) harbors different kinetics than our stable Cys580Ala LLCPK1 line, exhibiting a 
significantly larger Km for DA than WT (2.43 ± 0.19 versus 1.62 ± 0.16 µM, *p<0.05) 
and no statistical change in its maximal uptake velocity (254.3 ± 61.9 versus 143.0 
± 27.8 pmol/min/mg, p>0.05). Interestingly, Cys90Ala rDAT is also characterized 
by an increase Km for DA compared to WT (Figure 14) (2.86 ± 0.40 versus 1.50 ± 
0.24 µM, * p<0.05) with no detectable change in uptake velocity (126.4 ± 20.43 
versus 140.6 ± 9.29 pmol/min/mg, p>0.05). These results are summarized in Table 
1.  
These studies further explored the role DAT palmitoylation sites contribute 
to the DA reuptake process. Though they did not reveal a significant contribution 
of these sites to maximal velocity of DA transport, which is contrary to our previous 
characterization of the stably expressed Cys580Ala transporter, they did  
70 
 
  
Figure 11. Saturation analyses of Cys6Ala rDAT. LLCPK1 cells transiently 
transfected ~36 h with WT or Cys6Ala rDAT cDNA before analysis for their 
respective DA uptake kinetic characteristics. Upper panel: is a Michaelis-
Menten graph displaying surface normalized [3H]DA saturation analyses with 
increasing DA concentrations (0.32-20 µM). The mean uptake values ± S.E. of 
four independent experiments are shown. Bottom left: histogram represents 
Michaelis-Menten constant for DA uptake saturation experiments n=4, Km = 
1.63 ± 0.24 versus 2.09 ± 0.68, p>0.05 µM (mean ± S.E.M.). Bottom right: The 
histogram shows Vmax values for surface normalized DA uptake saturation 
experiments n=4, Vmax = 165.8 ± 7.8 versus 186.7 ± 27.6 pmol/min/mg, p>0.05 
(mean ± S.E.M.). Statistical analyses were performed by Student’s t-test.  
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Figure 12. Saturation analyses of Cys580Ala rDAT. LLCPK1 cells transiently 
transfected ~36 h with WT or Cys580Ala rDAT cDNA before analysis for their 
respective DA uptake kinetic characteristics. Upper Panel: Michaelis-Menten 
graph representing surface normalized [3H]DA saturation analyses with 
increasing DA concentrations (0.32-20 µM). The mean uptake values ± S.E. of 
three independent experiments are shown. Bottom Left: Histogram 
representing the Michaelis-Menten constant (Km) for DA uptake saturation 
experiments n=3, 2.43 ± 0.19 versus 1.62 ± 0.16 µM, *, p<.05 C580A versus 
WT (mean ± S.E.M.). Bottom Right: The right histogram displays Vmax values 
for surface normalized DA uptake saturation experiments n=3, 254.3 ± 61.9 
versus 143.0 ± 27.8 pmol/min/mg, p>0.05. (mean ± S.E.M.). Statistical 
analyses were performed by Student’s t-test.  
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Figure 13. Saturation analyses of Cys6/580Ala rDAT. LLCPK1 cells 
transiently transfected ~36 h with WT or Cys6/580Ala rDAT cDNA before 
analysis for their respective DA uptake kinetic characteristics. Upper Panel: 
Michaelis-Menten plots of surface normalized [3H]DA saturation analyses in 
increasing DA concentrations (0.32-20 µM). The mean uptake values ± S.E. 
of seven independent experiments are shown. Bottom Left: Histogram 
representing Michaelis-Menten constant (Km) for DA uptake saturation 
experiments n=7, Km = 2.19 ± 0.14 versus 1.80 ± 0.15 µM, p>0.05 (mean ± 
S.E.M.). Bottom Right: The histogram shows Vmax values for surface 
normalized DA uptake saturation experiments n=7, 137.0 ± 24.4 versus 
129.3 ± 19.0 pmol/min/mg, p>0.05 (mean ± S.E.M.). Statistical analyses 
were performed by Student’s t-test.  
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Figure 14. Saturation analyses of Cys90Ala rDAT. LLCPK1 cells transiently 
transfected ~36 hours with WT or Cys90Ala rDAT cDNA before analysis for 
their respective DA uptake kinetic characteristics. Upper panel is surface 
normalized [3H]DA saturation analysis with increasing DA concentrations (0.32-
20 µM). The mean uptake values ± S.E. of four independent experiments are 
shown. Bottom left panel is a histogram representing the Michaelis-Menten 
constant (Km) for DA uptake saturation experiments n=4 2.86 ± 0.40 versus 
1.50 ± 0.24 µM, *p<0.05. The bottom right panel is a histogram showing Vmax 
values for surface normalized DA uptake saturation experiments n=4, 126.4 ± 
20.43 versus 140.6 ± 9.29 pmol/min/mg, p>0.05. Statistical analyses were 
performed by Student’s t-test.  
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rDAT Line: Km (µM) Vmax (pmol/min/mg) 
Cys6Ala 1.63 ± 0.24 165.8 ± 7.8 
Cys580Ala 2.43 ± 0.19* 254.3 ± 61.9 
Cys6/580Ala 2.19 ± 0.14 137.0 ± 24.4 
Cys90Ala 2.86 ± 0.40* 126.4 ± 20.43 
Table 1. Summary of palmitoylation deficient rDATs DA transport kinetics 
versus WT. Cys6Ala: Km = 1.63 ± 0.24 versus 2.09 ± 0.68, p>0.05 µM; Vmax = 
165.8 ± 7.8 versus 186.7 ± 27.6 pmol/min/mg, p>0.05. Cys580Ala: 2.43 ± 0.19 
versus 1.62 ± 0.16 µM, *p<0.05; 254.3 ± 61.9 versus 143.0 ± 27.8 pmol/min/mg, 
p>0.05. Cys6/580Ala: Km = 2.19 ± 0.14 versus 1.80 ± 0.15 µM, p>0.05; Vmax = 
137.0 ± 24.4 versus 129.3 ± 19.0 pmol/min/mg, p>0.05. Cys90Ala: 2.86 ± 0.40 
versus 1.50 ± 0.24 µM, * p<0.05; 126.4 ± 20.43 versus 140.6 ± 9.29 
pmol/min/mg, p>0.05. Statistical analyses were performed by Student’s t-test 
of means ± S.E.  
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reveal that the apparent affinities for DA of two of the transporter types (Cys580Ala 
and Cys90Ala) were significantly increased – visualized by the significant increase 
in their respective Michaelis-Menten constants. To determine how the relative 
contribution of these DAT palmitoylation sites and the cellular palmitoylation micro 
environment contribute to DA transport, these DAT palmitoylation site mutants 
were treated with the irreversible acyltransferase inhibitor 2-bromopalmitate 
(2BP)374,375 and analyzed for DAT functional outcomes.    
  Global Palmitoylation Inhibition with 2BP Effect on DA Uptake   
2BP was initially demonstrated to reduce synaptosomal DAT-mediated DA 
uptake via decreasing DAT palmitoylation344. Here, LLCPK1 cells expressing each 
of the transiently produced Cys -> Ala DAT mutants were pre-incubated with 7.5 
µM 2BP for 90 minutes at 37oC and 5% CO2 prior to DA uptake with 3 µM DA 
containing the 10 nM [[FJ4]3H]DA tracer for 30 minutes in a 37oC water bath. 
Subsequently, these cells were lysed with 1% Tx-100 for 20 min at RT and the 
contents were collected and analyzed for radioactivity by scintillation counting 
(Figure 15). 
The results of these experiments suggest a synergistic relationship between 
DAT palmitoylation and global palmitoylation events. The WT transporter exhibited 
the largest DA uptake downregulation by 2BP which, as all its potential 
palmitoylation sites remain intact, stands to reason (Figure 15a) (52.33 ± 9.28 WT 
treated versus WT control, **p<0.01, n=3). The Cys6Ala (Figure 15b) and 
Cys580Ala DATs (Figure 15c) experienced similar downregulation patterns 
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Figure 15. 2BP downregulation of DA uptake decreases with 
palmitoylation-deficient rDATs. Cells transiently producing WT, 
Cys6Ala, or Cys580Ala rDATs for ~36 hours were incubated with 7.5 µM 
2BP for 90 min at 37oC and 5% CO2 prior to [3H]DA uptake analysis. DA 
uptake data are presented as %control 52.33 ± 9.28 WT treated versus 
WT control, **p<0.01, n=3. 74.05 ± 5.82 Cys6Ala treated versus Cys6Ala 
control, **p<0.01, n=6. 68.63 ± 10.89 Cys580Ala treated versus 
Cys580Ala control, *p<0.05, n=4. 80.83 ± 4.97 Cys6/580Ala treated 
versus Cys6/580Ala control, *p<0.05, n=3. Statistical analyses were 
performed by Student’s t-test of mean ± S.E. These results indicate 
mutational ablation of rDAT palmitoylation sites reduces 2BP efficiency 
in reducing DAT-mediated DA uptake. 
 
A) B) 
C) D) 
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(74.05 ± 5.82 Cys6Ala treated versus Cys6Ala control, **p<0.01, n=6; 68.63 ± 
10.89 Cys580Ala treated versus Cys580Ala control, *p<0.05, n=4). The loss of the 
single palmitoylation site reduced the 2BP-induced DAT down regulatory effect 
without completely abating it. The Cys6/580Ala DATs were even further resistant 
to 2BP induced DAT down-regulation (80.83 ± 4.97 Cys6/580Ala treated versus 
Cys6/580Ala control, *p<0.05, n=3) (Figure 15d). The Cys90Ala rDATs have yet 
to be tested by this methodology. Eliminating the palmitate-accepting residues 
from DAT attenuated the 2BP precipitated loss of DA uptake in an almost 
stoichiometric manner, as individual loss-of-palmitoylation-site rDATs display less 
reuptake loss than WT but more than the double site mutant (Figure 16). The 
double palmitoylation site mutant, however, still undergoes significant 2BP-
promoted reuptake loss, implicating S-palmitoylation events on Cys90 or within the 
DAT interactome playing a role in stabilizing DAT function; i.e. syntaxin 1a is an 
acyl-protein 376,377 whose interaction with DAT modulates DA reuptake. Though the 
effect protein S-acylation has on this interaction has yet to be studied, syntaxin 1a 
palmitoylation could either induce or inhibit its DAT interaction, rendering it an 
iteration of a non-DAT palmitoylation event affecting DAT function. 
Palmitoylation Deficient rDATs Display Altered DA efflux 
Understanding the DA efflux phenomenon is of paramount importance to 
DAT-targeted pharmaceutical interventions for psychiatric disorders, particularly 
ADHD378,379. Indeed, nonsynonymous hDAT single nucleotide polymorphisms 
exhibiting phenotypic aberrant DA release have been associated with ADHD380  
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Figure 16. Significant correlation between 2BP-induced DAT 
downregulation and number of DAT palmitoylation sites. A Pearson 
correlation coefficient of 0.9570 indicates the efficiency of 2BP in limiting 
DAT-mediated DA uptake is strongly correlated to the number of 
palmitoylation sites present on DAT. 
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and Parkinsonism256. This DA export process is pharmacologically induced by DAT 
substrates like AMPH226,381 and other AMPH congeners382. While many distinct 
molecular mechanisms integrate at DAT to contribute to DAT-mediated reverse 
DA transport233,237,240, N-terminal phosphorylation of the transporter is perhaps the 
best-known229. As DAT phosphorylation contributes to efflux and has a reciprocal 
interplay with DAT palmitoylation, DAT palmitoylation may exert influence over 
DAT-mediated basal and AMPH-stimulated DA efflux mechanisms.  
The palmitoylation site Cys to Ala rDATs were subjected to the biochemical 
efflux assay. This process entails: DAT forward transport to ‘load’ the cells with a 
DA mixture containing a [3H]DA radiotracer in KRH; washout of free radiolabel on 
ice with 4oC KRH; addition of efflux buffer (KRH alone for basal or KRH with 10 µM 
AMPH for stimulated efflux); collection of efflux buffer after 1 minute; lysis and 
collection of uptake control cells; analysis of all collected lysates and supernatants  
for radioactivity. Data are presented as % internal [3H]DA which is derived from 
basal or AMPH treated supernatant counts divided by corresponding uptake 
control counts then multiplied by 100. The palmitoylation deficient rDATs were 
transiently transfected into LLCPK1 cells and compared to WT for differences in 
both basal and/or 10µM AMPH-induced DA efflux (Figure 17). The Cys6Ala rDAT 
mutation (Figure 17a) produced an inhibition of both basal and AMPH-generated 
efflux (**p<0.01 C6A basal versus WT basal n=5; *p<0.05, C6A AMPH versus WT 
AMPH n=5). The Cys580Ala rDAT (Figure 17b) displays no significant change in 
basal DA release (p>0.05 Cys580Ala basal versus WT basal, n=4) but does 
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Figure 17. Cys6 and Cys580 impose opposite effects on DA reverse 
transport. [3H]DA efflux was analyzed by our biochemical reverse transport 
assay. Data are expressed as % internal [3H]DA. 100% internal DA was 
determined by scintillation counting of lysate from loaded cells which received 
no efflux buffer. C6A: **p<0.01 C6A Basal versus WT Basal n=5; *p<0.05, C6A 
AMPH versus WT AMPH n=5. C580A: p>0.05 Cys580Ala Basal versus WT 
Basal, n=4; *p<0.05 Cys580Ala AMPH versus WT AMPH, n=4. C6/580A: p>0.05 
Cys6/580Ala Basal versus WT Basal; p>0.05 Cys6/580Ala AMPH versus WT 
AMPH, n=3. p>0.05 Cys90Ala Basal versus WT Basal; p>0.05 Cys90Ala AMPH 
versus WT AMPH, n=4. Statistical analyses were performed by ANOVA with 
Tukey’s post hoc test of mean ± S. E. These results indicate Cys6 acylation 
events may support the DA efflux paradigm while Cys580  palmitoylation may 
oppose it.  
A) 
C) 
B) 
D) 
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potentiate AMPH-induced release (*p<0.05 Cys580Ala AMPH versus WT AMPH, 
n=4), and both Cys90Ala (p>0.05 Cys90Ala basal versus WT basal; p>0.05 
Cys90Ala AMPH versus WT AMPH, n=4) and Cys6/580Ala rDATs presented no 
alterations to either basal or AMPH-stimulated DA efflux. (p>0.05 Cys6/580Ala 
basal versus WT basal; p>0.05 Cys6/580Ala AMPH versus WT AMPH, n=3).  
These data demonstrate that elimination of rDAT palmitoylation sites does 
indeed affect the DAT-mediated DA release mechanism; losing Cys6 results in 
ablated efflux patterns while mutation of Cys580 slightly, though not statistically 
significantly, induced increased basal DA efflux and statistically enlarged AMPH-
induced release. Interestingly, the combination mutant, Cys6/580Ala rDAT, 
displayed neither altered basal nor altered AMPH DA efflux relative to WT, 
alleviating both Ala6 and Ala580 rDAT efflux phenotypes (Figure 17c). Cys90Ala 
rDAT also has unchanged basal and AMPH-triggered DA release, this, combined 
with its Km and surface anomalies, suggest a palmitoylation event at Cys90 may 
contribute to DAT trafficking and stabilization of a TM domain vital for DA uptake. 
 Global Palmitoylation Inhibition by 2BP Effect on DA Efflux   
 Ala580 rDATs have elevated basal phosphorylation, and treating 
synaptosomes with 2BP generates increased whole protein phosphorylation of 
native rDAT347. This information, along with the data from the previous study 
(Figure 17), lend credence to the idea that both DAT palmitoylation and the cellular 
palmitoylome cooperate in coordinating the DAT-mediated DA efflux mechanism. 
To further explore this cooperativity, LLCPK1 cells expressing WT or one of the 
82 
 
palmitoylation deficient rDATs were incubated with 7.5µM 2BP for 90 minutes in 
KRH prior to analysis for DA efflux (Figure 18). 
 Induction of DA efflux by 10 µM AMPH from the WT transporter was 
potentiated by treatment with 2BP (Figure 18a) (**p<0.01 WT 2BP AMPH versus 
WT AMPH, n=5), and basal 2BP-stimulated efflux levels approach higher levels 
than control basal though not yet statistically significant (p>0.05 WT 2BP basal 
versus WT basal, n=5). However, 2BP basal levels are also not statistically 
different than control AMPH-stimulated efflux (p>0.05 WT 2BP basal versus WT 
AMPH, n=5) suggesting further experiments may demonstrate 2BP to generate 
AMPH-like DA efflux. Ala6 rDATs (Figure 18b) also display greater AMPH-induced 
efflux after 2BP treatment than its control AMPH counterpart (**p<0.01 C6A 2BP 
AMPH versus C6A AMPH, n=6) and this mutant exhibited no alteration to basal 
efflux levels (p>0.05 C6A 2BP basal versus C6A basal, n=6). The Cys580Ala 
(Figure 18c) mutation does not result in altered basal or AMPH-stimulated DA 
efflux after 2BP treatment (p>0.05 C580A 2BP Basal versus C580A basal, n=5; 
p>0.05 C580A 2BP AMPH versus C580A AMPH, n=5). Likewise, the Cys6/580Ala 
rDATs (Figure 18d) display DA efflux signatures which are unaffected by 2BP 
pretreatment (p>0.05 C6/580A 2BP Basal versus WT Basal, n=3; p>0.05 C6/580A 
2BP AMPH versus C6/580A AMPH, n=3). Cys90Ala rDAT has yet to be analyzed 
by this methodology.   
Discussion 
 These studies demonstrate DAT thioacylation may occur at multiple sites 
distinct from Cys580, which is the site previously identified in WT transporters.  
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Figure 18. 2BP affects DA efflux. [3H]DA efflux was analyzed by our 
biochemical reverse transport assay. Cells transiently expressing either 
WT, Cys6Ala, or Cys580Ala rDATs were incubated with 7.5µM 2BP for 90 
min at 37oC and 5% CO2 after which DA reverse transport assays were 
conducted.  WT: p>0.05 WT 2BP Basal versus WT Basal, n=5; **p<0.01 
WT 2BP AMPH versus WT AMPH, n=5. C6A: p>0.05 C6A 2BP basal 
versus C6A Basal, n=6; **p<0.01 C6A 2BP AMPH versus C6A AMPH, 
n=6. C580A: p>0.05 C580A 2BP Basal versus C580A basal, n=5; p>0.05 
C580A 2BP AMPH versus C580A AMPH, n=5. C6/580A: p>0.05 C6/580A 
2BP Basal versus WT Basal, n=3; p>0.05 C6/580A 2BP AMPH versus 
C6/580A AMPH, n=3. Statistical analyses were performed by ANOVA with 
Tukey’s post hoc test of means ± S.E.  
A) B) 
C) D) 
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The evidence provided identifies Cys6, located on DAT’s distal N-terminus, and 
Cys90, nestled amidst the head groups of the exofacial PM leaflet atop DAT TM1, 
as the likely additional sites of this modification. This report also details the DA 
transport kinetic impact resultant from ablation of these acylated residues, surface 
transporter population vicissitudes, and the regulation of DA efflux exerted by DAT 
palmitoylation in particular, as well as palmitoylation in general. These results echo 
and expand upon previous DAT palmitoylation reports344,347: homeostasis of DAT 
and cellular palmitoylation events are crucial for synaptic DA homeostasis.  
 To understand the impact post translational modifications exert upon their 
modified protein, it is vital to understand where they occur. Initial DAT 
palmitoylation site exploration344 utilized bulk [3H]palmitate incorporation into Cys 
mutant DATs and elucidated Cys580 of rDAT as the major locus of radiolabel 
incorporation. This method was unable to eliminate the presence of other sites of 
DAT thioacylation as a significant amount of residual Cys580Ala radiolabeling 
remained. Unfortunately, the additional palmitoylation locations were also not 
readily discoverable by ABE (Figure 1), a procedure used for its more rapid 
repeatability (days versus weeks/months) and increased sensitivity342, of single 
Cys residue point mutations (Cys90, due to its location, was not considered at this 
time). Several different biochemical approaches were then necessary. Initially, all 
Cys residues were changed to Ala save one to discern if the single remaining 
intracellular Cys is a PAT substrate. Palmitoylation analysis by ABE of these DAT 
mutants identified Cys6 as a palmitoylation site – at least when no other 
intracellular Cys residues are available for this modification (Figure 2). Importantly, 
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this methodology also demonstrated Cys580 as a palmitoylation site. Figure 3 
demonstrates ABE of the combination Cys6/580 rDAT mutant displays ABE 
signatures near rDATs possessing only Cys135, Cys341, or Cys522 (Figure 2), 
while DATs with these two sites and lacking the other three intracellular Cys 
residues (Cys135/341/522Ala) presents WT-level palmitoylation. These results 
rule out Cys135, 341, and 522 as palmitoylation sites and implicate Cys6 in 
addition to Cys580 as a site for this modification. The loss of Cys6 not resulting in 
reduced palmitoylated DAT signatures is troubling, though a possible explanation 
is the transporters lacking this residue undergo increased acylation of Cys580 or 
other residues.      
To strengthen the mutagenesis data, in vivo determination of N-terminal 
DAT palmitoylation occurring at distinct primary sequence loci was made. This was 
achieved through enzymatic and chemical DAT fragmentation and subsequent 
ABE purification of the palmitoylated peptides. The protocols for these experiments 
were derived from previous studies on site localization of binding of photoaffinity 
ligands to the DA permeation pathway of DAT366–368,383. The result was an 
amalgam of proteolysis, ABE, and epitope-specific immunoblotting techniques. 
This protocol was first applied with Asp-N, use of which generates an 
approximately 19 kDa molecular weight rDAT peptide which is readily detected by 
immunoblotting with an antibody against an N-terminal DAT antigen369. This multi-
step palmitoylated peptide isolation procedure demonstrated that in vivo DAT 
palmitoylation occurs at regions other than the C-terminus (Cys580) and the 
occurrence is likely Cys135, Cys6, or least likely, Cys90 (Figures 4 & 5). CNBr 
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chemical proteolysis of DAT occurs predominantly at the methionine cluster in TM2 
and produces a peptide lacking Cys135 (Figure 6)366–368,383. This procedure 
produced a palmitoylated DAT peptide of approximately 11 kDa representing Cys6 
as the likely palmitoylated residue (Figure 7); the composite of this result and the 
mutagenesis results effectively eliminate Cys135 as a DAT palmitoylation site. 
The CNBr fragmentation/ABE process was next applied to Cys6Ala and 
Cys135Ala rDATs expressed in LLCPK1 cells (Figure 8), and the result was 
surprising: the Cys6Ala rDAT still harbored a palmitoylated N-terminus. This is 
most likely due to an additional palmitoylated residue, likely Cys90, in this peptide. 
ABE analysis of Cys90Ala rDATs displayed significantly reduced ABE readout than 
the WT transporter (Figure 9). The fractional values of Cys90Ala (0.96 ± 0.05) 
compared to WT (1.34 ± 0.13) imply this DAT mutant maintains around 70% WT 
palmitoylation. This is a lower stoichiometric level than Cys580 and, as the two 
experiments testing Cys580Ala acylation only removed ~50% of the signal, leaves 
room for the possibility of additional palmitoylated residues – like Cys6.  
Surface biotinylation assays were used to probe for alterations to 
transporter PM population changes which would allude to altered trafficking 
patterns provoked by loss of a palmitoylation site (Figure 10). The initial DAT 
palmitoylation study described no surface alterations upon Cys580 mutation or 
2BP treatment though chronic palmitoylation inhibition resulted in expedited DAT 
degradation344. Here, the Ala6, Ala580, and Ala6/580 rDATs exhibit steady-state 
PM levels akin to the WT form; surprisingly, Ala90 rDAT shows increased surface 
transporter levels. The uptake kinetic data demonstrate unaltered DA saturation 
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transport kinetics for Cys6Ala (Figure 11) and Cys6/580Ala (Figure 13). The 
mutation of the Cys90 (Figure 14) and Cys580 (Figure 12) both generated 
increased Km relative to WT. No mutation generated significant alterations to 
maximal DA uptake velocity. These data demonstrate DA reuptake parameters are 
dependent upon lapidating events at certain residues, but not others. These 
experiments were conducted via transient induction of the full length DATs which 
may explain the Cys580 result differing from the data obtained from stably-
expressing cell lines347. Acute translation and modification of the DAT protein may 
vary between tissue, cell line, and protein production procedure. 
The magnitude of 2BP-induced down-regulation of DA transport decreased 
linearly with loss of palmitoylated Cys residues (Figures 15 & 16). 
WT>Cys580Ala>Cys6Ala>Cys6/580Ala. This stands to reason as 2BP would 
produce less DAT-subjective effects as less DAT-lipidation events are occurring. 
The remaining 2BP-induced down-regulation of the Cys6/580Ala potentially results 
from loss of Cys90 palmitoylation or reduced protein-protein interactions which are 
propitiated by palmitoylating events. These analyses should be performed on both 
Cys90Ala rDAT and the triple combination Cys6/90/580Ala rDAT.  
The DAT substrate AMPH384 which stimulates N-terminal DAT 
phosphorylation229 and interacts with vesicular monoamine transporters385 is a 
powerful inducer of DA efflux. Palmitoylation deficient rDAT mutants exhibited 
different AMPH-induced efflux patterns. A Cys6 palmitoylation event seems to 
support efflux as loss of this residue incurs ablated basal and AMPH induced 
release, while Cys580 palmitoylation events oppose efflux as elimination of this 
88 
 
Cys potentiates AMPH responsiveness. Global and DAT-specific palmitoylation 
was examined further by 2BP inhibition of the global palmitoylation process. 
AMPH-stimulation of DA release was potentiated by 2BP in the WT and Cys6Ala 
transporters and no basal increase of DA efflux was seen in any of the transporter 
populations.   
The rDAT palmitoylation site detection studies revealed Cys6 and Cys90 as 
potential additional loci of this modification. Palmitoylation of these residues would 
generate interesting structural and functional consequences. Fatty acid 
attachment to Cys6 of DAT’s distal N-terminus would likely result in the tethering 
of this peptide to membranous structures in proximity to it. Multiple transmembrane 
proteins undergo acylation of their NH2 termini: Phospholemman requires 
palmitoylation of N-terminal Cys residues 40 and 42 to blunt Na+-K+-ATPase 
activity386; The ATP-binding cassette transporters A1387 and G1388 require 
thioacylation of their NH2 domains for PM localization and cholesterol efflux onto 
their target lipoproteins. Tethering of DAT’s N-terminus was previously reported as 
being mediated by interactions with PIP2389,390 potentiating AMPH-induced DA 
efflux232, a characteristic shared with SERT391, though SERT-PIP2 interplay is not 
coordinated through its NH2 domain. The palmitoylation of Cys6 may operate 
synergistically with PIP2 to strengthen DAT’s N-terminal interaction with the PM, 
similar to the ‘kinetic trapping’392 phenomenon in which one lipid modification 
(frequently N-myristoylation or prenylation) weakly increases the target protein’s 
hydrophobicity enough to produce transient membrane interactions with DHHC 
populated membranes to further lipidate the protein, creating stronger membrane 
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affinity. This ‘kinetic trapping’ process has been documented to affect the function 
of several peripheral membrane proteins393–396.  Indeed, Cys6Ala rDATs display 
reduced basal and AMPH-induced efflux (Figure 17a), a phenotype similar to DAT 
interaction with PIP2 depleted membranes232,389 (summarized in Figure 19). Cys6 
acylation would also likely impact NH2-terminus interacting proteins; interactions 
between syntaxin 1a, dopamine D2 receptor, ubiquitin ligases, and protein kinases 
may be contingent upon or sterically inhibited by Cys6 palmitoylation. The 
neighboring amino acid, Ser7, is a phosphorylated residue, and one expects Cys6 
acylation to have significant implications for the phosphorylation status of Ser7, a 
scenario brought into clearer focus by the recent insight of the reciprocal 
relationship between DAT phosphorylation and palmitoylation347. It is interesting to 
speculate that palmitoylation is an additional DAT N-terminal post-translational 
modification coordinating the protein’s function in a ‘barcoding’ fashion analogous 
to diverse GPCR phosphorylation patterns activating different signaling, protein 
interaction, or endocytic outcomes397. Multiple proteins experience reciprocal 
palmitoylation and ubiquitination305,329. A DAT post-translational modification 
interplay has been demonstrated between phosphorylation-palmitoylation 
crosstalk347, and alluded to between DAT phosphorylation-ubiquitination398 where 
PKC activators induce enhanced DAT ubiquitination and degradation183,182, though 
these studies do not demonstrate concomitant PKC phosphorylation and 
ubiquitination of DAT. Cys6 palmitoylation may modulate both DAT ubiquitination 
and phosphorylation, creating another layer of detail in the picture of fine-tuned 
signaling assimilating at DAT’s NH2 peptide, marking it with phosphorylation,  
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Efflux 
Figure 19. Schematic of Cys6 palmitoylation tethering DAT’s N-
terminus to the plasma membrane. Cys6 palmitoylation would likely 
tether DAT’s N-terminal peptide to the plasma membrane. This 
tethering event may aid the DAT-mediated DA efflux process. 
Palmitoylation of this residue may also contribute to Lys3 and Lys5’s 
interaction with PIP2 phosphlipids as well as increase the likelihood of 
Syn1a interaction with the DAT N-terminus – both events which 
likewise increase DAT-mediated DA efflux. 
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ubiquitination, and now palmitoylation; an image which is also likely affected by 
cellular machinery cycling the palmitoylation status of Cys90. 
Cys90 thioesterification would likewise generate interesting outcomes. 
These suggest Cys90 to be an S-palmitoylation substrate (figure 9), Cys90Ala 
rDATs to have increased surface presence (Figure 10d), and increased Km for DA 
(Figure 14). The location of this residue precluded its inclusion into the initial 
acylation site exploration experiments as it is located on the exoplasmic leaflet of 
the PM. This location renders the possibility of S-palmitoylation on plasma 
membrane Cys90 being reversible unlikely, though a portion of the PPT enzymes 
are secreted399,400 so removal of the synapse-side palmitate is possible, but its re-
addition is unlikely. This, coupled with the findings that Cys90 is highly reactive to 
MTS reagents370,371, imply very few surface DATs are acylated at Cys90, 
implicating it as an intracellular phenomenon. Because the DHHC domain of the 
PAT enzymes lies proximal to the cytoplasmic portion of the membrane401, the 
intriguing palmitoylation/depalmitoylation cycle of Cys90 would occur with the co-
translational attachment of the fatty acid within the ER373,402; post-translational 
Cys90 will be oriented toward the organelle lumen or, while at the PM, 
extracellularly, without access to the PAT catalytic motif. The depalmitoylation of 
Cys90, therefore, is likewise a lumen event - indicating a PPT-catalyzed process 
rather than APT. PPT’s have been classically associated with lysosomal protein 
degradation287–289; however, an increasing body of evidence implicates 
malfunctioning endosomal290 and synaptic vesicular400,403 PPT1 in infantile 
neuronal ceroid lipofuscinosis (INCL) etiology. The presence of this enzyme is 
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essential for accurate turnover of several key palmitoylated protein components of 
vesicular fusion machinery403 - syntaxin 1a376,377, SNAP25404–407, cysteine string 
protein408,409, synaptobrevin410, and synaptotagmin I404,411–413. The significantly 
elevated PM population of the Cys90Ala mutant may be an effect of losing 
palmitoylation of Cys90 which may sequester the acylated DATs in endosomes; 
events which coordinate vesicular DA egress and require activated PPT1 for 
recycling of vesicular machinery may concomitantly draw endosomal DATs to the 
PM for reuptake of the released transmitter via depalmitoylation of Cys90. Thus 
the Ala90 rDAT would lose endosomal retention and display elevated PM 
expression (Figure 10d). It is interesting to note that the lack of loss of surface 
transporters upon treatment of rat striatal synaptosomes with 2BP may be an effect 
of losing Cys90 acylation, which would replenish plasma membrane DAT 
populations that traffic away from the plasma membrane in response to loss of 
Cys580 acylation, an event which is known to antagonize DAT degradation344. This 
implies palmitoylation at different locations of the same substrate protein (90 
versus 580) yield opposite phenotypic results.   
DAT-mediated substrate translocation requires transition through many 
physical permutations of the transporter in an alternating access fashion159,160; 
synaptic DA, two Na+172 ions and one Cl-173 ion cosubstrates bind to an outward-
open conformation triggering conformational progression through an occluded 
structure and ultimately achieving an inward-open state whereupon substrate and 
cosubstrates are released into the cytoplasm157. The substrate permeation 
pathway of DAT involves amino acid residues from TMs 1, 3, 6, and 8155. The 
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analysis of the DA uptake saturation kinetics revealed Cys90Ala rDATs have 
significantly increased Km for DA uptake than their WT counterparts (Figure 14). 
From the immediately preceding account of how palmitoylation of Cys90 may 
come about, it is unlikely the loss of Ala90’s apparent DA affinity is due to loss of 
lipidation of this residue, but rather loss of the chemical interactions supported by 
the sulfhydryl side chain with polar head regions of the exofacial leaflet of the PM. 
This may produce an instability in TM1, which moves significantly during the DA 
transport process, precipitating overall reduction of the integrity of this portion of 
the substrate translocation route, hampering these DAT’s ability to interact with 
DA. Additionally, a cholesterol molecule binds in a groove formed by TMs 1, 5, and 
7155, and an alanine at rDAT position 90 may alter conformational dynamics of this 
region. Cholesterol has been demonstrated to be an important influencer of DAT 
conformation156 and, therefore, function, stabilizing both forward and reverse DA 
transport187. Thus disruption of Cys90 producing a loss of cholesterol-DAT 
interaction could also explain the loss of apparent affinity for DA presented by the 
Ala90 DATs (Figure 15).  
The report on Cys580Ala uptake saturation kinetics yielded surprising 
results (Figure 13). Though these experiments, like the previous study of 
Cys580Ala rDAT347, were performed in LLCPK1 cells, these DATs were generated 
by transient transfection while the former were stably produced. Here the Km was 
significantly higher than WT, and Vmax, though apparently elevated, was not 
significantly higher. The past report found these transporters have an unchanged 
Km for DA but a significantly reduced maximal DA transport velocity347. This may 
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be due to altered modification and binding partner interactions of the transiently 
versus stably translated proteins or the transfection reagent affecting plasma 
membrane characteristics, with trickle-down effect on plasma membrane protein 
(DAT) function. Further studies need to be done to determine whether stable or 
transient transfection better reflects the in vivo biological reality.   
The experiments reporting the 2BP effect on palmitoylation-deficient DATs’ 
DA uptake capabilities attempt to expand upon previous results demonstrating that 
2BP treatment downregulates [3H]DA uptake in rat striatal synaptosome 
preparations344, and differentiate between the effects of global and DAT-specific 
palmitoylation events on DA uptake (Figure 15). 2BP stimulated loss of DA 
reuptake was positively correlated to the number of acylation sites present on the 
DATs (Figure 16); The WT transporter population succumbed to the greatest 2BP 
generated DA transport loss while the combination Cys6/580Ala transporters were 
affected the least. This result stands to reason as a reduction in the number of 
DAT acylation sites would indicate the residual loss of function (or gain in the case 
of other proteins414) induced by 2BP to be a result of more global palmitoylation 
inhibition than DAT-subjective palmitoylation blockade. It is, therefore, 
unsurprising that the Cys6/580Ala rDATs display the least 2BP created loss of 
function. Additionally, it should be noted that the mutation of these sites may 
produce a priori effects which would otherwise be accounted for by 2BP treatment; 
i.e., DAT-interacting proteins may lose their binding interaction due to mutagenesis 
of the Cys residue(s) rather than a binding partner losing its palmitoylation moiety 
via 2BP rendering it incapable of interacting with DAT. The presence of both Cys6 
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and Cys580 may be vital to establish some binding partner interactions; though, 
mutagenesis-induced loss of these would-be-interactions produce no change in 
uptake kinetics of the Cys6/580Ala rDATs (Figure 13). The Cys90Ala and 
Cys6/90/580Ala transporters need to be assessed by this method as it would be 
interesting to see if the triple combination DAT-palmitoylation deficient mutant 
displays no DA transport loss upon 2BP treatment.  
 The efflux experiments (Figures 17 and 18) reveal that S-acylation 
significantly contributes to DAT-mediated reverse DA transport process. The 
hitherto discovered DAT structural and functional factors which support AMPH-
stimulated DA release are: the NH2-terminus in general362; the specific 
phosphorylation thereof228; its PIP2-mediated tethering to the PM232;  the induction 
of a channel-like mode of the transporter, enabling quantum-like transmitter 
release233; ion conductance promulgating PM depolarization234 producing Ca2+ 
influx235,236 and propagation of neuronal excitability415; elevated accumulation of 
intracellular Na+ ions requisite for DA efflux237; and AMPH action at the cognate 
vesicular transporter239,240. The mutation of Cys6 blunted both basal and AMPH 
stimulated efflux while Cys580 alteration potentiated AMPH’s DA releasing action 
(Figure 17a). This Cys6Ala phenotype may be due to losing PIP2-mediated DAT 
N-terminal-PM interplay whose structural outcomes and concomitant protein 
interactor differences confer dampened DA efflux characteristics to the transporter. 
Ala580 rDAT’s increased capacity for AMPH stimulated release may be due to its 
susceptibility toward inherent elevated phosphorylation and is therefore more 
prone to AMPH effects. Likewise, palmitoylation of Cys580 stabilizes DA 
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reuptake347 and losing this modification may allow easier conformational 
isomerization of the transporter and greater substrate access to its inward-open 
form, easing substrate efflux. The contrary efflux patterns of Cys6Ala and 
Cys580Ala rDATs cancel out in the Cys6/580Ala transporters which behave like 
WT DATs upon AMPH treatment, and in like manner Cys90Ala does not deviate 
from the AMPH-WT phenotype. 
 General cellular palmitoylation was demonstrated to contribute significantly 
to the DAT-mediated efflux paradigm (Figure 18). WT transporters display 2BP-
basal release like AMPH-stimulated release, and 2BP and AMPH induce additive 
DA release effects on WT DATs. This is partially due to the ability of 2BP to induce 
transporter phosphorylation347, but also loss of lipidation of other proteins which 
would propitiate DA efflux parameters: The Na+/K+-ATPase requires palmitoylation 
for its function321 and loss thereof would induce efflux-favorable cytoplasmic 
accumulation of Na+ ions; DAT-interacting D2 receptors undergo S-acylation136,416 
and loss of its palmitoylation may alter its interaction with the transporter, altering 
the nature of AMPH-stimulated DA release; 2BP-reduced syntaxin 1a acylation 
may support its interaction with DAT, especially if, like DAT, these modifications 
interact reciprocally at syntaxin 1a, as the SNARE protein’s enhanced 
phosphorylation has been demonstrated to increase its DAT partnering and 
promotion of reverse DA transport417. The 2BP treatment of Cys6Ala and 
Cys580Ala (Figures 18b and c) transporters generated results congruent with the 
AMPH treatment of these transporters alone (Figures 17a and b). Cys6Ala DATs 
have potentiated AMPH-induced DA release after incubation with 2BP (Figure 
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18b), consistent with losing acylation events at Cys580, and Cys580Ala DATs 
display unaltered AMPH-stimulated DA release patterns (Figure 18c), consistent 
with losing Cys6 acylation events as the Cys6Ala mutation attenuated DA efflux 
(Figure 17a). 2BP had no effect on the induction of either basal or AMPH-propelled 
efflux from Cys6/580Ala DATs (Figure 18d). As with the 2BP effect on DA uptake 
of these transporters (Figure 15d), this may be due to the structural or interactor 
characteristics which would otherwise be altered by 2BP.   
 This study relates the potential for two additional rDAT S-palmitoylated 
residues, Cys6 and Cys90, and the impact these residues have on both forward 
and reverse DA transport; Cys6 acylation significantly affects the dynamic of the 
NH2-domain and supports DA efflux, and Cys90 acylation has significant 
implications for the trafficking of the transporter and the residue is important to the 
integrity of the substrate permeation pathway. Importantly, this study implicates 
palmitoylation in playing an important role in the complex DA efflux process. Our 
lab has demonstrated the hyper effluxing hDAT coding variant Ala559Val380 to be 
deficient in S-palmitoylation, and it is conceivable, in light of this study, that 
improper palmitoylation of DAT may contribute to this aberrant efflux phenotype. It 
may be possible, therefore, to achieve reversal of this anomalous DA efflux 
characteristic via therapeutic intervention at the level of DAT palmitoylation. The 
theory of targeting protein palmitoylation to alleviate disease states is not new418, 
and with the emergence of multiple illnesses being associated with aberrant 
protein S-palmitoylation332,419, psychiatric disorders involving DA homeostasis may 
be beneficially impacted through modulation of DAT S-acylation.  
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Methods  
 Cell Culture and Site Directed Mutagenesis 
 Lilly Laboratory Cell Porcine Kidney (LLCPK1)420 parental cells or LLCPK1 
cells stably expressing WT or mutant rDATs were grown in Dulbecco’s Modified 
Eagle Medium (DMEM) containing 5% fetal bovine serum, 100 µg/mL 
penicillin/streptomycin, and supplemented with 400 µg/mL of the selection reagent 
Geneticin (G418) for stably expressing cell lines. Cells were maintained in a 
humidified incubator with 5% CO2 at 37oC. Cys to Ala rDAT mutant DNA constructs 
were generated using the Stratagene QuickChange® PCR kit from template WT 
rDAT pcDNA 3.0 vector cDNA, and nucleic acid substitution was confirmed by 
sequencing (Eurofins MWG). For generation of multiple Cys to Ala substitutions, 
sequential addition of mutations were performed such that Cys135Ala mutation 
was introduced into the Cys6Ala rDAT template and subsequently Cys341Ala 
mutation was introduced into the Cys6/135Ala rDAT template until all the rDAT 
cDNA constructs containing only one intracellular Cys residue were produced. 
 Transfection 
 For generation of cell lines stably expressing WT or mutant rDAT 
constructs421, LLCPK1 parental cells were seeded into 12-well plates and grown to 
~50% confluence. At this point the cells were transfected. X-tremGENE 
transfection reagent was mixed with plasmid DNA (1.4 µg of DNA/well) at a 
reagent:DNA ratio of 3:2 in OptiMEM for 20 min at ambient temperature after which 
the transfection complex was added to each well dropwise. After ~36 hours, the 
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cells were then transferred to a culture flask to undergo selection of expressing 
cells via 800 µg/mL G418 treatment. After two subculture passages at this G418 
concentration, the cells were collected, the plasma membranes were harvested, 
and expression of rDAT was analyzed by immunoblotting with the anti-DAT mouse 
monoclonal antibody MAb16. If the transfection was successful, the stably 
expressing rDAT cells were maintained in 400 µg/mL of G418 for all subsequent 
uses. For transient production of the desired rDATs, LLCPK1 parent cells were 
seeded into 24-well (0.5 µg DNA/well) or 100 mM plates (5 µg DNA/plate) and 
grown to ~80% confluence. X-tremeGENE transfection reagent was mixed with 
plasmid DNA at an X-tremeGENE:DNA ratio of 3:2 in OptiMEM for 20 min at 
ambient temperature. After the incubation, the transfection construct was added to 
each well containing 0.5 mL of DMEM for 24-well plates or 5 mL of DMEM for 100 
mM plates. Experiments were performed ~36 hours post-transfection.  
 SDS-PAGE and Western Blotting 
 DAT proteins and peptides were denatured in Laemmli sample buffer (SB: 
125 mM Tris-HCl, 20% glycerol, 4% SDS, 200 mM DTT, 0.005% bromophenol 
blue) and were electrophoretically resolved using 4-20% polyacrylamide gels 
alongside a ColorBurst protein standard. Proteins were then transferred to a 
transfer buffer (25 mM Tris-HCl, 192 mM Glycine, 0.1% SDS, 10% methanol) -
equilibrated polyvinylidene fluoride (PVDF) membrane after which blocking was 
performed with a 3% BSA/PBS buffer. Primary MAb16 antibody was diluted 
1:1,000 in the blocking solution and the blocked PVDF membrane was incubated 
in this antibody solution for 1 hour at ambient temperature. After five washes the 
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membrane was incubated in alkaline phosphatase (AP)-linked anti-mouse IgG 
secondary antibody diluted to a 1:5,000 ratio in blocking buffer for 1 hour followed 
by 5 additional washes. 3 mL of Immun-Star™ AP substrate (Bio-Rad) was applied 
to the membrane and incubation proceeded for 5 min at ambient temperature. 
Generated chemiluminescent Western blot band intensities were quantified using 
Quantity One® software (Bio-Rad).     
 Plasma Membrane Preparation 
rDAT-LLCPK1 cells expressing the indicated DATs were grown in 150 mm 
plates to ~90% confluency. Cells were washed twice with Buffer B (0.25mM 
sucrose, 10 mM triethanolamine, and pH was adjusted to 7.8 with 100 mM acetic 
acid), scraped, and collected in Buffer B containing a protease inhibitor cocktail of 
1 µM phenylmethylsulfonyl fluoride (PMSF) and 5 µM Ethylenediaminetetraacetic 
acid (EDTA) at 4oC. Cells were then pelleted via centrifugation at 3,000 x g for 5 
min at 4oC, supernatants were removed, and the cell pellets were suspended in 
Buffer C (0.25 M sucrose, 10 mM triethanolamine, 1 mM EDTA, and the pH was 
adjusted to 7.8 with 100 mM acetic acid) and subsequently homogenized using 30 
up and down strokes in a Dounce homogenizer. Cellular debris and nuclei were 
cleared from the homogenates by centrifugation at 800 x g for 10 min. The post-
nuclear supernatant was collected and centrifuged at 18,000 x g for 12 min, and 
the resulting plasma membrane pellet was suspended in sucrose phosphate (SP) 
buffer (10 mM sodium phosphate, 0.32 M sucrose, pH 7.4 with 1 µM PMSF and 5 
µM EDTA).   
 Synaptosome Preparation 
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Male Sprague-Dawley rats weighing between 200 and 300g were 
decapitated, and striatal hemispheres were excised, weighed, and stored in ice-
cold SP buffer. The striata were homogenized in 2 mL ice-cold SP buffer with 30 
up and down strokes in a glass-Teflon homogenizer, diluted with a further 8 mL 
SP buffer, and centrifuged at 3000 x g for 2 min at 4oC. The supernatant fraction 
was isolated and subjected to an additional centrifugation at 15,000 x g for 12 min. 
The resulting P2 pellet encompassing synaptosomes was suspended in SP buffer 
with protease inhibitors and the tissue was diluted to 20 mg/mL using the original 
wet weight of the striatal tissue.  
 Asp-N Endoproteinase Proteolysis 
Striatal synaptosomes or membranes from rDAT expressing LLCPK1 cell 
were prepared as described above and divided equally into two microfuge tubes. 
The preparations were acetone precipitated with an acetone to sample volume 
ratio of 4:1 for 1 hour at -20oC. The pellets were suspended in SP buffer and equal 
volumes were divided between one control and one Asp-N treated microfuge tube. 
The same volume of SP was added to the negative control test tube and SP buffer 
containing 2 μg/mL endoproteinase Asp-N was added to the treatment test tube 
creating a final endoproteinase concentration of 1 μg/mL. For membrane 
preparations, 0.1% SDS (v/v) was added to the digestion and control samples. 
Enzymatic digestions were carried out for 45 minutes at ambient temperature with 
nutation.  Both samples were then centrifuged at 18,000 x g for 12 min at and the 
resultant pellet was used for further experimentation.   
CNBr Chemical Proteolysis 
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Equal volumes of striatal synaptosomes or membrane preparations of the 
indicated rDAT-expressing LLCPK1 cells were divided into CNBr treated or control 
microfuge tubes and acetone precipitated with 4x sample volume for 1 hour at -
20oC. The samples were centrifuged at 18,000xg for 10 minutes and supernatants 
were removed.  Precipitated experimental pellets were then suspended in 70 µL 
formic acid, 10 µL water, and 20 µL 5M CNBr (1M final concentration) or 70 µL 
formic acid and 30 uL water for untreated samples.  Digestion was performed for 
1 hour at 25oC in the dark. CNBr was removed via 3 repetitions of dilution with 
900uL water and lyophilization. Final pellets were then used in subsequent 
experimentation.  
Acyl-Biotinyl Exchange 
Our ABE method was adapted from Wan et al341 where detection of 
palmitoylated proteins are described in three steps: Free cysteine thiols are 
blocked; thioester linked palmitoyl groups are specifically removed by 
hydroxylamine (NH2OH); and the previously palmitoylated and now free sulfhydryl 
groups are biotinylated. Membranes isolated from WT rDAT or rDAT mutant 
LLCPK1 cells or rat striatal synaptosome preparations were solubilized in 250 µL 
of ABE lysis buffer (50 mM HEPES pH 7.0, 2% SDS (w/v), 1 mM EDTA) containing 
protease inhibitor and 20mM methyl methanethiosulfonate (MMTS) to react with 
unbound Cys sulfhydryl moieties and incubated for one hour at ambient 
temperature. MMTS was removed by a 1 mL acetone precipitation and 
centrifugation at 18,000 x g for 10 min. The pellet was dissolved in 250 µL 4SB 
ABE buffer (50 mM Tris, 5 mM EDTA, 4% SDS, pH 7.4) and remnant MMTS was 
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removed by an additional 1 mL acetone precipitation and centrifugation. The pellet 
was then subjected to a further acetone wash. The pellet was suspended in 200 
µL 4SB buffer and thioesterified palmitate molecules were specifically removed by 
hydroxylamine (NH2OH); The sample was split equally (100 µL) into negative 
control (800 µL, 50 mM Tris-treated) and NH2OH -treated (1.4 mM) halves and 
incubated at ambient temperature for 30 min with end-over-end mixing. The free 
sulfhydryl groups were reacted with 100 µL (0.4 mM final concentration) of a 
sulfhydryl-specific biotinylating reagent, HPDP-biotin in the Tris or NH2OH 
mixtures. The now HPDP-biotin-containing samples were incubated for 3 min in a 
37oC water bath then at ambient temperature for 1 hour. Excess NH2OH and biotin 
reagents were removed by the 4:1 acetone to sample volume precipitation, 
centrifugation at 18,000 x g, supernatant aspiration, 250 µL 4SB pellet suspension, 
1 mL acetone precipitation, centrifugation at 18,000 x g, supernatant aspiration, 1 
mL acetone wash, centrifugation at 18,000 x g, and supernatant aspiration 
workflow. The final pellet was suspended in 75 µL ABE lysis buffer and 10 µL of 
this was set aside for total DAT immunoblotting while 65 µL was added to 50 µL of 
a 50%  slurry of Neutravidin resin in 1500 µL Tris buffer to affinity purify the 
biotinylated proteins or peptides overnight at 4oC with nutation. Unbound peptides 
were washed away by three cycles of 8,000 x g centrifugation and 900 µL radio 
immunoprecipitation assay buffer (RIPA: 1% Tx-100, 1% sodium deoxycholate, 
0.1% SDS, 125 mM sodium phosphate, 150 mM NaCl, 2 mM EDTA, 50 mM NaF). 
Proteins and peptides were eluted from the final pellet by incubation in 2x Laemmli 
104 
 
SB for 20 min at ambient temperature. Samples were then subjected to SDS-
PAGE, and immunoblotted with mouse anti-rDAT primary antibody (MAb16). 
2BP DA Uptake Assay  
LLCPK1 parent cells were grown in 24-well plates until ~80% confluent then 
were transiently transfected with the indicated rDAT DNA. 36 hours prior to the 
assay, the cells were washed with 0.5 mL 37oC KRH buffer and resupplied with 
KRH buffer with or without 7.5 µM 2BP for 90 min at 37oC and 5% CO2. After the 
2BP incubation, DA uptake was conducted for 30 min at 37oC with 3 µM total DA 
containing 10 nM [3H]DA. Excess DA was rapidly washed out with KRH buffer and 
the cells were lysed with 1% Tx-100 for 20 min at ambient temperature. Lysates 
were collected and analyzed for [3H] content by liquid scintillation counting. 2BP 
uptake data are presented as % uptake control.   
 DA Efflux Assay 
LLCPK1 parent cells were seeded onto 24-well assay plates at 50,000 
cells/well and allowed to grow to ~80% confluence (~24 h).  Cellular production of 
WT or mutant DATs was induced by transient transfection for ~36 hours prior to 
assay. DAT-expressing LLCPK1 cells were loaded via DA DAT-mediated uptake 
of 3 µM DA containing 10 nM [3H]DA for 30 minutes in 37oC Krebs Ringer/HEPES 
buffer (KRH, 25 mM HEPES, 125 mM NaCl, 2.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM 
MgSO4, 5.6 mM glucose, 1.3 mM CaCl2, 1.1 mM ascorbic acid). Extracellular DA 
was washed out 3 times with 4oC KRH on ice, and the assay plate was transferred 
back to the water bath and 37oC KRH efflux buffer with or without 10 µM AMPH 
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was rapidly added to avoid cell drying and displacement upon buffer addition. The 
efflux buffer was collected after one minute and analyzed for radioactive content; 
one column of cells received no efflux buffer and was lysed with 1% Triton X-100 
for 20 min at ambient temperature and served as the total internal [3H]DA control 
and was analyzed in parallel for [3H] content by liquid scintillation counting. The 
efflux values are expressed as a percent of the total intracellular [3H]DA. Where 
indicated cells were incubated with 7.5 µM 2BP in KRH for 90 min prior to the 30 
min load portion of the experiment. 
 DA Uptake Saturation Analysis 
Saturation analyses were performed on LLCPK1 cells transiently producing 
WT or mutant DATs in 24-well assay plates 36 h post-transfection. The cells were 
rinsed once and then resupplied with 0.5 ml of 37oC KRH buffer. The DA 
concentrations used were varied from 0.32 µM to 20 µM containing 10 nM [3H]DA 
and uptake was performed in triplicate for 8 min; nonspecific uptake was 
determined by DA uptake in the presence of 100 µM (-)-cocaine. After 8 min, cells 
were rapidly washed 2 times with ice-cold KRH buffer and solubilized in 1% Tx-
100 for 20 min at ambient temperature with rocking. Radioactive DA present in the 
collected lysates was assessed by liquid scintillation counting. Kinetic values were 
analyzed using Prism software, and Vmax values for each DAT line were normalized 
to transporter surface levels determined by surface biotinylation assays performed 
in parallel for each experiment.  
 Surface Biotinylation  
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LLCPK1 parent cells were seeded onto 24-well assay plates and grown to 
~80% confluence at which point 12 wells of each plate were transiently transfected 
with the indicated rDAT plasmid 36 hours prior to the biotinylation assay. After 
transfection the cells were washed three times with ice cold Hank’s balanced salt 
solution containing Mg+ and Ca2+ ions (HBSS Mg-Ca: 1mM MgSO4, 0.1 mM CaCl2, 
pH 7.4), and subsequently incubated twice with 0.5 mg/mL of membrane-
impermeable sulfo-NHS-SS-biotin for 25 min on ice with rocking. The biotinylation 
reagent was removed and the reaction was quenched by two sequential 
incubations with 100 mM glycine in HBSS Mg-Ca for 20 min on ice with rocking. 
Cells were washed with HBSS Mg-Ca and lysed with 125 µL RIPA buffer 
containing protease inhibitor in each well after which the lysates from 12 wells (one 
full DAT line) were collected in a 2 mL microcentrifuge tube. 100 µg of protein from 
each lysate were incubated with NeutrAvidin beads overnight at 4°C with nutation. 
The beads were washed three times with RIPA buffer and the bound protein was 
eluted with 32 µl of SB followed by SDS-PAGE and immunoblotting for DAT with 
MAb16.  
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CHAPTER 3 
EFFECTS OF THE PARKINSON-INDUCING NEUROTOXINS MPP+ AND 6-
OHDA ON DOPAMINE TRANSPORTER FUNCTION AND MODIFICATION 
Abstract 
Synaptic action of the neurotransmitter dopamine (DA) is primarily 
terminated by reuptake into presynaptic dopaminergic neurons via dopamine 
transporters (DATs). DATs are integral plasmalemmal proteins whose reuptake 
function is tightly coordinated by interplay between the post translational 
modifications phosphorylation and palmitoylation. The psychostimulant 
amphetamine (AMPH) is a DAT substrate known to empty sequestered DA from 
vesicles and induce protein kinase C (PKC)-dependent DAT phosphorylation, 
resulting in reverse transport of DA (efflux) and greatly increased DA signaling. 
Elevated DA concentrations similar to those produced by AMPH create neurotoxic 
conditions as DA oxidation produces free radicals and hinders mitochondrial 
respiration, thus strict spatial and temporal control of cytosolic and synaptic DA is 
essential for neuronal health. DA induced oxidative stress is an important 
pathogenic mediator in Parkinson disease (PD), and animal models of PD are 
generated by the neurotoxins 1-methyl-4-phenylpyridinium ion (MPP+) and 6-
hydroxydopamine (6-OHDA) which selectively target DAT-expressing neurons, 
are translocated to the cytosol by DAT, and perturb the oxidative balance within 
the cell to produce the nigrostriatal DA neuron death observed in PD. It is therefore 
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intriguing to investigate DAT-involved mechanisms in terms of PD etiology as 
atypical DAT function could contribute to DA oxidative stress and is hypothesized 
to play a role in other neurological disorders including attention deficit/hyperactivity 
disorder (ADHD) and addiction. DAT expression occurs around synaptic terminals, 
along axons, and on dendritic spines, and efflux via DATs located on dendrites in 
the substantia nigra has been shown to diminish dopaminergic signaling. It is 
possible, therefore, for aberrant regulation and localization of DA clearance and 
DAT-mediated DA efflux to profoundly influence the excitability of neurons and play 
a significant role in neurodegeneration in the progression of PD. This is even more 
interesting in the light of recent studies revealing DAT polymorphisms in patients 
diagnosed with a psychiatric disorder or early onset PD that display an elevated 
basal DA efflux phenotype. In this study, we are investigating the effect of DAT 
substrates and PD-inducing neurotoxins on DAT phosphorylation, palmitoylation, 
down-regulation, and reverse transport to better understand aberrant DAT 
mechanisms which may contribute the onset of PD. Our findings indicate MPP+ 
and 6-OHDA differentially alter DAT function. 6-OHDA inhibits basal and 
attenuates PMA-induced DAT phosphorylation, does not significantly reduce DA 
uptake, and decreases DA efflux. MPP+ does not change basal or PMA stimulated 
DAT phosphorylation yet it induces significant DA efflux which may be an 
additional means by which MPP+ produces neurodegeneration. This MPP+ induced 
efflux was not abolished by pretreatment with the PKC inhibitor 
bisindolylmaleimide (BIM). Although AMPH-induced efflux was blunted after BIM 
treatment, significant efflux remained, supporting evidence of mechanisms 
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independent of PKC mediated DAT phosphorylation for the stimulation of DA 
efflux. 
Introduction 
 Parkinson Disease (PD) is the second most common neurodegenerative 
illness and its prevalence is expected to increase proportionately with the size of 
aging populations422. PD pathology423 is characterized by progressive, selective424 
loss of substantia nigra (SN) pars compacta dopamine (DA) neurons and 
aggregation of proteinaceous fibril superstructures, comprised primarily of α-
synuclein, known as Lewy bodies425. The clinical presentation of this illness, 
though phenotypically heterogeneous, is manifest through aberrant locomotor 
output in the form of bradykinesia, resting tremor, postural instability, and/or 
rigidity426; however, onset of these symptomatic traits generally does not appear 
until 66%-80%352 of SN DAergic neurons are lost, generating further striatal DA 
deficiency427 and causing the resultant motor dissonance to occur. These data 
spurred interest in finding prodromal manifestations of PD, and associations 
between disease onset and manifold pre-motor symptoms were established428,429: 
olfactory malfunction430; rapid eye movement sleep behavior disorder431,432; 
constipation433,434; and depression435,436 with antidepressant use have been 
identified as potential pre-motor symptoms in PD development. PD treatment 
methodologies437 target motor symptoms of the disorder and primarily entail 
replenishing DA function via  increasing striatal DA concentration through elevating 
DA synthesis with the product of its rate-limiting enzymatic step, levodopa, 
mimicking synaptic DA action by DA receptor agonists, or attenuating enzymatic 
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DA degradation with monoamine oxidase and/or catechol-o-methyl transferase 
inhibitors438. While these pharmacotherapies improve quality of life, their long-term 
use, coupled with the progression of the disease, result in increasing severity of 
symptoms including dementia, dyskinesia, and psychosis439,440.  
 At a biochemical level, PD etiology has been linked to several protein  
and organellar malfunctions. Inherited PD stems from polymorphisms of genes 
coding for α-synuclein, E3 ubiquitin ligase, leucine-rich repeat kinase 2, and other 
proteins253,441, while idiopathic PD derives from numerous risk factors like 
exposure to pesticides and use of beta blockers442. The resultant synuclein 
aggregation induces cellular damage through endoplasmic reticulum stress, 
mitochondrial impairment443, neuroinflammation444, and reactive oxygen species 
production445, all of which induce cell death. As previously mentioned, the locus 
and cell type of these apoptotic events is a common link between inherited and 
idiopathic PD and that is consistent loss of substantia nigra DA neurons. A 
peculiarity of this subset of neurons is their high expression of the DA transporter 
(DAT), the high-affinity DA reuptake protein139,446. Indeed, the extent of PD-
induced loss of DAergic neurons from the brain’s primary DA pathways is greatest 
in the nigrostriatal tract352, followed by ventral tegmental area-originating 
mesocoritcal and mesolimbic structures447,448, while the tuberoinfundibular tract 
remains largely unaffected424. These losses positively correlate with both DAT 
mRNA449–451 and protein expression452,453 in these regions. It is for this reason DAT 
has been hypothesized as a molecular gateway through which PD pathogenicity 
occurs251,454.   
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 Two neurotoxic compounds used extensively in laboratories to create 
facsimiles of PD for study in multiple model systems operate as DAT substrates; 
their experimental efficacy is due to their transport selectivity by DAT and therefore 
poison neurons specifically expressing DATs. These compounds, 6-
hydroxydopamine (6-OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) (Figures 1 & 2), induce the DAergic neuron losses characteristic of PD, 
and do so through overlapping biochemical mechanisms455. Under physiologic 
conditions 6-OHDA induces cell death after rapid auto-oxidation456 and generation 
of oxygen-derived free radical species457,458, perhaps through iron-catalyzed ROS 
activity459,460. Additionally, 6-OHDA inhibits complex I of the mitochondrial electron 
transport chain461,462 and induces neuronal death primarily through apoptotic 
pathways463. MPTP neurotoxicity occurs after its monoamine oxidase conversion 
to 1-methyl-4-phenylpyridinium (MPP+) in astrocytes464,465, flux from these cells 
through organic cation transporter 3466 or extraneuronal monoamine transporter467, 
and neuronal entry via DAT. Once in the cytosol, MPP+ is sequestered into vesicles 
through VMAT2468,469 which empties vesicular DA into the cytosol, producing its 
oxidation by-products and their concomitant oxidative damage470,471. MPP+ 
likewise inhibits mitochondrial ATP production443,472, but unlike 6-OHDA, has been 
shown to destabilize cytoskeletal structures473,474, and cause acute increased 
striatal DA release475,476. The toxic functional outcomes of these compounds are 
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Figure 1. Chemical structures of 6-OHDA and MPP+. Chemical structures of 
Dopamine (top), 6-hydroxydopamine (middle), and 1-methyl-4-
phenylpyridinium (bottom). 
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Figure 2. Known neurotoxic mechanisms of 6-OHDA and MPP+. Schematic 
diagram of DA, 6-OHDA, and MPP+ Neurotoxic mechanisms.  After synthesis, 
DA is packaged into vesicles via the vesicular monoamine transporter where it 
is trafficked to the plasma membrane for exocytotic release into the synapse. 
Cytosolic DA metabolism is known to generate ROS. DA can be oxidized to 
form reactive quinones that react further on to form neurotoxic compounds and 
protein adducts. MPP+ is enzymatically generated in glial cells via MAO.  6-
OHDA and MPP+ enter neurons through DAT and induce their toxic effects by 
inhibition of complex I of oxidative phosphorylation, formation of ROS by lipid 
peroxidation, or disruption of cytoskeletal integrity. 
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dependent upon their DAT-mediated entry into neurons477–479, and many of their 
DAT-specific effects have hitherto been unexplored.  
This study investigates the biochemical effects exerted by the PD-
generating neurotoxins upon heterologously expressed DATs; DA reuptake, DA 
reverse transport, DAT phosphorylation, and DAT palmitoylation changes induced 
by 6-OHDA and MPP+ were assessed. Our findings reveal that, despite sharing 
multiple cytotoxic mechanisms, 6-OHDA and MPP+ have striking dissimilarities in 
regards to DAT phosphorylation, DA uptake downregulation, and DAT-mediated 
DA efflux. Significantly, this study further investigates the DA efflux phenomenon 
associated with early onset PD and ADHD, an event recapitulated by MPP+, and 
highlights the extreme caution needed in prescribing or using pharmaceuticals 
inducing carrier-mediated DA efflux. 
Results 
 6-OHDA and MPP+ Competitively Inhibit DAT-mediated DA Uptake 
 To investigate the concentrations at which DA uptake by WT rDATs in 
LLCPK1 expression systems were inhibited by 6-OHDA and MPP+, competition 
uptake assays were utilized. The half maximal inhibitory concentration (IC50) was 
determined for the LLCPK1 – WT rDAT model by [3H]DA uptake assays with 
unchanged 0.5 µM DA in the presence of increasing concentrations (10-7 to 10-1 
M) of 6-OHDA or MPP+ (Figure 3). The IC50 for 6-OHDA was approximately 1mM 
(1025 ± 185 uM, n=2 independent experiments performed in triplicate), and the  
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Figure 3. MPP+ has a 16-fold greater potency than 6-OHDA for the inhibition 
of DA uptake.  LLCPK1-rDAT cells were assayed for [3H]DA uptake activity in 
the presence of 10-7- 10-1 M 6-OHDA or MPP+. Reactions contained 0.5 µM DA 
with the indicated inhibitor concentration and were conducted at 37°C for 8 min 
after which cells were washed, lysed, collected, and analyzed for radioactivity by 
scintillation counting. IC50 values for 6-OHDA and MPP+ were determined by 
non-linear regression analysis and data are presented as mean ± S.E. of two 
experiments carried out in triplicate. Foster and Vaughan, unpublished data. 
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MPP+ IC50 was 64.4 ± 10.3 µM (n=2 independent experiments performed in 
triplicate). While these compounds do not have particularly high affinity for the DA 
translocation site on DAT (for reference, see DA saturation analysis studies in 
chapter II), they do exhibit competitive inhibition of DA uptake, indicating 
competition for the primary substrate permeation pathway of DAT in LLCPK1 cells. 
This, of course, corresponds with what has been known about these compounds 
for some time – they require DAT to enter DAergic neurons to exert their neurotoxic 
effects. Also, as DA uptake was competitively inhibited by 6-OHDA and MPP+, 
these experiments indicate the LLCPK1 – DAT model system is valid to utilize for 
further experimentation with these compounds. 
 6-OHDA and MPP+ Induce Downregulation of DAT Activity 
 The extent to which the neurotoxic DAT substrates are able to downregulate 
DAT uptake capacity was next interrogated. 20 µM of 6-OHDA, MPP+, and DA in 
parallel with 400 nM phorbol-12-myristate-13-acetate (PMA), a PKC-activator 
known to down-regulate DAT function yet not requiring DAT activity to enter the 
cell’s cytoplasm, were applied to LLCPK1 cells expressing WT rDAT 30 minutes 
prior to washout with 4oC KRH and [3H]DA uptake testing (Figure 4). In these 
experiments, MPP+ (p<0.01 versus 6-OHDA) and DA (p<0.05 versus 6-OHDA) 
induced significantly greater downregulation of DAT function than did 6-OHDA, 
though no substrate attenuated DAT activity to the extent of PMA. These results 
indicate these DAT substrates produce down regulatory effects on DAT-mediated 
DA uptake, but do so, perhaps, by varying means. That 6-OHDA induces 
significantly less uptake attenuation may indicate it affects DAT internalization or 
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Figure 4. 6-OHDA induces DAT downregulation to a significantly lesser 
extent than DA or MPP+. LLCPK1-rDAT cells were pretreated with vehicle, 400 
nM PMA, 20 µM DA, 20 µM 6-OHDA, or 20 µM MPP+ at 37°C for 30 min 
followed by rapid washout at 4°C prior to assay for DA uptake.  Down-regulation 
is reported as the percent difference in transport activity between the vehicle 
and substrate or PMA pretreatments.  Data are presented as mean ± S.E. of 
two experiments carried out in triplicate. **p<0.01 MPP+ versus 6-OHDA, 
*p<0.05 DA versus 6-OHDA. Foster and Vaughan, unpublished data. 
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regulatory pathways differently than MPP+ or DAT’s cognate substrate, DA; though 
MPP+ induced effects similar to DA on DAT activity, this by no means indicates 
they operate through similar mechanisms to blunt DAT function.   
 Incubation of 6-OHDA and MPP+ on DAT-Expressing Cells Affects DA 
Uptake and Requires Functional DATs   
To delineate whether the functional downregulation generated from the 
activity of 6-OHDA and MPP+ results from the active DAT-mediated translocation 
of these compounds into the cell or allosteric, extracellular binding events, DA 
uptake activity was assessed after incubation of these substances in the absence 
or presence of the high affinity DAT inhibitor, cocaine. This was assessed via 
incubating LLCPK1 cells expressing WT rDAT with 20 µM of each neurotoxin in 
parallel with 20 µM DA and 400 nM PMA for 30 minutes prior to drug washout and 
[3H]DA uptake analysis (Figure 5). As a control to demonstrate that any effect 6-
OHDA or MPP+ produces on DA uptake results from their DAT-mediated entry into 
the cell, the indicated incubations were simultaneously performed in the presence 
of 100 µM of cocaine. The results of these experiments show incubation with MPP+ 
(p<0.01), like PMA (p<0.05) but unlike 6-OHDA (p>0.05) significantly reduces 
subsequent DAT mediated DA uptake vs. control. The concomitant incubation of 
the tested compounds with cocaine successfully blocked the MPP+-induced DA 
uptake losses observed in the absence of cocaine (p>0.05). The short incubation 
period utilized (30min) hints at acute effects on intrinsic DAT properties such as 
conformational alterations, binding partner interactions, post-translational  
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Figure 5. Neurotoxin downregulation of DAT requires their DAT-mediated 
transport. LLC-PK1-rDAT cells were pretreated with vehicle, 400 nM PMA, 20 
µM DA, 20 µM 6-OHDA, or 20 µM MPP+ at 37°C for 30 min with or without 100 
µM cocaine followed by rapid washout at 4oC prior to assay for DA uptake with 
3 uM DA containing 10 nM [3H]DA for 8 min at 37oC. Cells were rapidly washed 
and lysates were collected and analyzed for radioactive DA content by 
scintillation counting. Uptake is reported as the percent vehicle control. 
**p<0.01 MPP+ versus Control, *p<0.05 PMA versus Control. These results 
indicate MPP+ induces significant DAT activity downregulation and requires 
DAT-mediated cell entry to achieve this effect. 
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modifications, or transporter internalization, rather than the generation of cell-
toxifying reactive oxygen species, which take more time to be produced and built 
up to an extent at which they can induce significant cell damage. These 
compounds require DAT-mediated cell entry. 
 Neurotoxin Effects on DAT-Mediated Reverse DA Transport 
Reverse transport (efflux) of DA via DAT has been implicated in the 
neuropathology of ADHD and Parkinson’s disease. It follows, then, that an 
additional mechanism by which 6-OHDA or MPP+ may be able to induce its 
neurotoxic effects is the generation of DAT-mediated DA efflux. To test this we 
performed a biochemical efflux assay which involves ‘loading’ DAT-expressing cell 
system with [3H]DA through DAT-mediated uptake for 30 min, followed by 3 
washouts of extracellular radiolabeled DA with 4oC KRH on ice. Efflux is 
subsequently induced by the addition of the 37oC KRH efflux buffer containing 
vehicle (to determine the basal efflux level), AMPH (strong DAT-mediated DA 
efflux inducer, positive control), or the indicated neurotoxin for 5 minutes. This 
buffer is then collected and assayed for radioactivity by scintillation counting. 
These efflux experiments were conducted at the sub IC50 concentrations used in 
the previous experiments (Figure 6) as well as the determined IC50 values (1 mM 
for 6-OHDA and 60 µM for MPP+) (Figure 7) determined from the experiments 
described in figure 1. Interestingly, the results of the efflux studies strongly 
implicate MPP+ as an efflux inducing compound at both 20 µM (p<0.05 versus 
Basal) and its IC50, 60 µM (p<0.01 versus Basal). Additionally, though not  
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Figure 6. 20 µM MPP+ induces DA efflux. LLCPK1 cells expressing wild 
type rat DAT were grown in 24-well plates and subjected to the DA efflux 
assay. Efflux was induced by the addition of 37o KRH buffer alone to 
determine basal efflux or KRH containing 10 µM AMPH, 20 µM 6-OHDA, 20 
µM MPP+ to determine compound-induced DA efflux (n=3). The efflux buffer 
was collected after 5 minutes and analyzed for radioactivity by scintillation 
countining. *p<0.05 MPP+ versus Basal and 6-OHDA, ***p<0.001 MPP+ 
versus AMPH, ***p<0.001 AMPH versus Basal and 6-OHDA. Data are 
presented as % internal [3H]DA. Statistical analyses were performed by 
ANOVA with Tukey’s post hoc test of mean ± S.E. These results indicate 
MPP+ induces DAT-mediated DA efflux. 
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Figure 7. IC50 concentration of neurotoxin effect on DA efflux. LLCPK1 
cells expressing wild type rat DAT were grown in 24-well plates and 
subjected to the biochemical DA efflux assay. Efflux was induced by the 
addition of 37o KRH buffer alone to determine basal efflux or KRH containing 
10 µM AMPH, 1 mM 6-OHDA, 60 µM MPP+ to determine drug-induced efflux 
(n=3). The efflux buffer was extracted after 5 minutes and assayed for 
radioactivity by scintillation counting. **p<0.01 MPP+ versus Basal and 
AMPH, ***p<0.001 MPP+ versus 6-OHDA, ***p<0.001 AMPH versus Basal 
and 6-OHDA. Statistical analyses were performed by ANOVA with Tukey’s 
post hoc test of mean ± S.E. These experiments confirm MPP+ is a strong 
inducer of DA efflux as the IC50 concentration produced marked increase in 
DA efflux. 
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statistically significant, 6-OHDA tended to lower DA efflux in rDAT LLCPK1 
systems at both 20 µM (p>0.05 versus Basal) and 1 mM (p>0.05 versus Basal). 
This same experiment paradigm was applied to human DAT (hDAT) 
expressing LLCPK1 cells to determine whether the same efflux event is produced 
by MPP+ interaction with the human DAT isoform (Figure 8). MPP+ did induce 
significantly increased levels of DA release relative to basal control from hDAT 
LLCPK1 cells (p<0.001 versus Basal). Additionally, 6-OHDA significantly reduced 
DA efflux from WT hDAT cells (p<0.01 versus Basal) supporting the trend seen 
with WT rDAT cells (Figures 6 & 7). These experiments reveal two distinct 
mechanisms by which neurotoxicity may occur: the AMPH-like rapid release and 
increase of extracellular DA concentration produced by MPP+, and the blunting of 
DAT-mediated DA release seen after 6-OHDA treatment, resulting in elevated 
cytosolic DA tone and increased potential for generation of DA oxidation species. 
To our knowledge, 6-OHDA attenuation of DA efflux represents the first finding of 
a DAT substrate blunting the DA efflux effect.  
 Inhibiting PKC Reduces Neurotoxin-Induced DA Efflux 
An important molecular mechanism involved in DAT-mediated DA efflux is 
phosphorylation of the transporter by PKC. To determine if this kinase’s activity 
contributes to the elevated DA efflux induced by MPP+ treatment or the reduced 
DA release event initiated by 6-OHDA exposure, the previously utilized 
biochemical DA efflux assay was conducted after inhibition of PKC with 10 µM of 
the PKC inhibitor bisindolemaleimide (BIM) during the 30 minute DA uptake load 
phase. 20 µM and IC50 concentrations of each neurotoxin were used on both BIM  
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Figure 8. 6-OHDA blunts DA efflux from WT hDATs. LLCPK1 cells 
expressing wild type human DAT were grown in 24-well plates and subjected 
to the biochemical DA efflux assay. Efflux was induced by the addition of 37o 
KRH buffer alone to determine basal efflux or KRH containing 10 µM AMPH, 1 
mM 6-OHDA, 60 µM MPP+ to determine drug-induced efflux (n=3). The efflux 
buffer was extracted after 5 minutes and assayed for radioactivity by scintillation 
counting. ***p<0.001 MPP+ versus 6-OHDA and Basal, **p<0.01 6-OHDA 
versus Basal, ***p<0.001 AMPH versus 6-OHDA and Basal. Statistical 
analyses were performed by ANOVA with Tukey’s post hoc test of mean ± S.E. 
This set of experiments further support MPP+ as an efflux inducer and 
demonstrate 6-OHDA as an inhibitor of the DAT-mediated DA efflux process. 
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treated and untreated LLCPK1-rDAT cells (Figures 9 & 10). Additionally, BIM 
inhibition of PKC was tested in regards to the AMPH-stimulated DA efflux 
mechanism as well (Figure 11). Both basal (p<0.01 versus Basal) and 20 µM 6-
OHDA treatment (p<0.01 versus Basal) saw reduced DA efflux upon BIM 
treatment relative to untreated basal release (Figure 9). These data demonstrate 
that steady-state PKC activity, and likely phosphorylation of DAT itself, significantly 
contributes to a homeostatic DA leak through DAT. The extent of this basal release 
is no doubt exacerbated by 30 minutes of DA intake; nonetheless, unstimulated 
DAT-mediated DA release activity is significantly lessened by PKC inhibition. That 
20 µM 6-OHDA release characteristics were further blunted by BIM treatment is 
unsurprising as both molecules likely function through different mechanisms to 
modulate DAT-mediated efflux. While at 1 mM, 6-OHDA may interfere with BIM-
induced mechanisms other than DAT phosphorylation through PKC, as the 5 
minute 6-OHDA exposure is likely insufficient to alter this DAT PTM, yet does 
relieve the BIM-induced DA efflux attenuation. Once again MPP+ induced 
significantly elevated DA efflux (Figure 10) at both 20 (p<0.05 versus Basal) and 
60 µM (p<0.001 versus Basal) concentrations relative to basal control values and 
the 60 µM event was reduced upon PKC inhibition (p<0.001 versus MPP+ 60 µM). 
BIM treatment preceding 20 µM MPP+-stimulated efflux did not significantly reduce 
the release pattern relative to the untreated 20 µM MPP+ paradigm (p>0.05 versus 
Basal) though this same BIM exposure did not eliminate the significant increase 
relative to the basal control release (p>0.05 20 µM MPP+ + BIM versus Basal). And 
though BIM treatment did not completely ablate 60 µM MPP+ activation of efflux 
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Figure 9. PKC inhibition effect on 6-OHDA DA efflux signature.  LLCPK1 
cells expressing wild type rat DAT were grown in 24-well plates and subjected 
to the DA efflux assay after BIM treatment. Efflux was induced by the addition 
of 37o KRH buffer alone to determine basal or KRH containing 20 µM or 1 mM 
6-OHDA (n=3) and collected 5 minutes subsequently and assessed for 
radioactivity by scintillation counting. Data are presented as % internal [3H]DA. 
100% internal [3H]DA was determined by lysing and assessing radioactive 
content of cells receiving no efflux buffer. **p<0.01 Basal versus Basal + BIM 
and 6-OHDA 20 µM + BIM, *p<0.05 6-OHDA 1 mM versus Basal + BIM and 6-
OHDA 20 µM + BIM. Statistical analyses were performed by ANOVA with 
Tukey’s post hoc test of mean ± S.E. 
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Figure 10. PKC inhibition reduces MPP+-induced DA efflux.  LLCPK1 cells 
expressing wild type rat DAT were grown in 24-well plates and subjected to the 
biochemical DA efflux protocol after BIM treatment. Efflux was induced by the 
addition of 37o KRH buffer alone to determine basal or KRH containing 20 µM 
or 60 µM MPP+ (n=3) and collected 5 min subsequently and assessed for 
radioactivity by scintillation counting. Data are presented as % internal [3H]DA. 
100% internal [3H]DA was determined by lysing and assessing radioactive 
content of cells receiving no efflux buffer. *p<0.05 Basal + BIM versus Basal, 
*p<0.05 MPP+ 20 µM versus Basal, ***p<0.001 MPP+ 60 µM and MPP+ 60 µM 
+ BIM versus Basal, ***p<0.001 MPP+ 60 µM versus Basal + BIM, MPP+ 20 
µM, MPP+ 20 µM + BIM, and MPP+ 60 µM + BIM. Statistical analyses were 
performed by ANOVA with Tukey’s post hoc test of mean ± S.E. These results 
indicate PKC activity contributes to the MPP+-stimulated DA efflux paradigm, 
but may not be the sole contributor to this process. 
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Figure 11. PKC inhibition reduces AMPH-stimulated DA efflux.  LLCPK1 
cells expressing wild type rat DAT were grown in 24-well plates and subjected 
to the DA efflux assay. Efflux was induced by the addition of 37o KRH buffer 
alone to determine basal or KRH containing 10 µM AMPH (n=6) and collected 
5 minutes subsequently and assessed for radioactivity by scintillation counting. 
Data are presented as % internal [3H]DA. 100% internal [3H]DA was determined 
by lysing and assessing radioactive content of cells receiving no efflux buffer. 
***p<0.001 Basal versus AMPH and AMPH + BIM, ***p<0.01 Basal + BIM 
versus AMPH and AMPH + BIM, *p<0.05 AMPH + BIM versus AMPH. 
Statistical analyses were performed by ANOVA with Tukey’s post hoc test of 
mean ± S.E. These studies confirm PKC contributes to, but is not the only 
mechanism by which AMPH-induced DA efflux occurs.  
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(p<0.001 versus Basal), it did greatly reduce 60 µM MPP+-induced efflux (p<0.001 
MPP+ 60 µM + BIM versus MPP+ 60 µM). This same pattern was achieved by 
AMPH-induced DA efflux (Figure 11). AMPH stimulation was significantly curtailed 
by PKC inhibition (p<0.001 AMPH + BIM versus AMPH). These experiments reveal 
that MPP+ stimulation of DA efflux utilizes at least one mechanism in common with 
AMPH, PKC activity, and perhaps, like AMPH, operates through additional 
mechanisms to induce DA efflux.  
Neurotoxin Effect on DAT Phosphorylation 
 To further understand the forward and reverse DA transport effects induced 
upon neurotoxin-exposed DATs, we assessed the effect of MPP+ and 6-OHDA on 
two prominent DAT post-translational modifications – phosphorylation and 
palmitoylation. Neurotoxin-induced DAT phosphorylation was assessed by 
radiolabeling with [32P] metabolically incorporated by kinase activity into rDATs 
expressed in LLCPK1 cells (Figure 12). These cells were treated with neurotoxins 
for 30 minutes with or without 200 nM PMA during which [32P] incorporation was 
conducted. Equal amounts of radiolabeled DATs were immunoprecipitated with a 
poly16 crosslinked protein A sepharose column, subjected to SDS-PAGE and 
autoradiography. This signal was then normalized to equal amounts of rDAT 
immunoblotted with MAb16 (Figure 13). Intriguingly, 6-OHDA significantly reduced 
both basal (p<0.01 6-OHDA versus Control) and PMA-stimulated (p<0.01 6-OHDA 
+ PMA versus Control + PMA) [32P]phosphorylation of rDAT relative to control in 
each condition in this expression system. This suggests the attenuated DA efflux 
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Figure 12. 6-OHDA inhibits basal and attenuates PMA-induced DAT 
phosphorylation.  rDAT-LLCPK1 cells labeled with 32PO4 were treated with 
vehicle, 1 mM 6-OHDA or 1 mM MPP+ for 30 min at 37°C. Vehicle or PMA 
treatment was conducted in parallel wells during the same incubation period. 
(Upper Panel)  Representative autoradiogram of poly 16 immunoprecipitated 
32PO4-labeled DATs.  (Lower Panel)  Quantification of 32PO4-labeled DAT band 
intensities from three independent experiments, **p< 0.01 (student’s t-test). 
Foster and Vaughan, unpublished observation. These results indicate one 
means by which 6-OHDA induces attenuation of DA efflux may be by inhibiting 
transporter phosphorylation. Also, MPP+ generates DA efflux without altering 
DAT phosphorylation. 
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Figure 13. Total DAT protein expression is unchanged after neurotoxin 
treatment. (Upper Panel) Representative immunoblot showing DAT protein 
levels in sample lysates from [32P] labeling experiments. (Lower Panel)  
Quantification of DAT content in rDAT-LLCPK1 cell lysates labeled with 32PO4; 
three independent experiments. These results demonstrate neurotoxin 
treatment does not induce loss of total transprter expression. Foster and 
Vaughan, unpublished finding. 
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effect generated by 6-OHDA upon DATs may involve blunting of DAT 
phosphorylation mechanisms. Also surprising was the discovery that MPP+ 
application does not affect basal (p>0.05 MPP+ versus Basal) or PMA-stimulated 
(p>0.05 MPP+ +PMA versus Basal + PMA) transporter phosphorylation, which is 
crucial for AMPH-stimulated DA efflux. This implies the drug induces carrier-
mediated DA efflux through mechanisms other than direct transporter 
phosphorylation, and the BIM-attenuated DA release occurs through inhibiting 
PKC phosphorylation of DAT-interacting proteins. The neurotoxin treatments were 
shown to alter DAT phosphorylation characteristics without altering total DAT 
protein levels (Figure 13).   
 Neurotoxin Effect on DAT Palmitoylation 
As DAT palmitoylation plays a role in the protein’s DA uptake stability344,347 
and is an additional mechanism involved in DAT-mediated DA efflux (Chapter 1), 
DAT palmitoylation was analyzed after neurotoxin treatment to discern if these 
compounds generate changes in this modification of DAT (Figure 14). To assess 
transporter palmitoylation alterations resultant from 6-OHDA or MPP+ treatment, 
rDAT-LLCPK1 cells were pretreated for one hour with IC50 concentrations of both 
neurotoxins after which membrane preparations were performed and acyl-biotinyl 
exchange (ABE) analysis was conducted. The ABE inquiry demonstrated these 
neurotoxins have no effect on rDAT palmitoylation at the concentration and time 
used. Perhaps longer treatment times will produce DAT palmitoylation changes, 
but their acute effects generated on DAT forward and reverse DA transport is 
independent of DAT palmitoylation modulation. At a 1 hour and 400 nM treatment  
133 
 
  
Figure 14. Neurotoxin effect on DAT palmitoylation. Membranes isolated 
from rDAT-LLCPK1 cells treated with vehicle, 400 nM PMA, 1 mM 6-OHDA, 
or 60 µM MPP+ for 1 hr at 37o C were subjected to ABE.  Hydroxylamine 
(NH2OH) removes palmitate and enables the subsequent binding of the 
sulfhydryl-specific HPDP-biotin thereby allowing for detection of 
palmitoylated protein via NeutrAvidin chromatography and western blotting 
(upper left panel). Band intensities from these blots are quantified and 
normalized to their corresponding total immunoblotted DAT signals shown in 
the lower panel. Statistical analysis was performed by ANOVA with Tukey’s 
post hoc test p>0.05, n=3.  
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paradigm, PMA also failed to reduce DAT palmitoylation. The concentration was 
chosen as it was used in the preceding experiments despite 1 µM being previously 
demonstrated to significantly reduce DAT palmitoylation347. 
 Discussion 
 The neuronal expression of DAT is strongly positively correlated with 
susceptibility of the neuron to death in the etiology and progression of PD449–453; 
as such, the aim of this study was to discern any DAT-specific effects produced by 
the  PD-inducing neurotoxins, 6-OHDA and MPP+, widely used in the medical 
science research of this disease. The experiments were conducted in the LLCPK1 
cell system stably expressing DATs. Competitive uptake assays (Figure 3) 
determined that 6-OHDA and MPP+ do compete for the transporter DA 
translocation site in this system and that their IC50 concentrations for it are 1 mM 
and 60 µM respectively. Figures 4 and 5 represent experiments performed which 
demonstrate these compounds downregulate DAT function and that their down 
regulatory effects are DAT-mediated transport dependent. The next set of results 
decisively confirm that MPP+ is an inducer of DA efflux at both 20 (Figure 6) and 
60 µM (Figure 7) concentrations from rDAT, an effect which is contributed to by 
functional PKC (Figure 10), and at 60 µM with hDAT (Figure 8). MPP+ was 
previously discovered to dramatically increase extracellular DA levels when 
perfused into the striatum480 and this release was DAT-dependent476, so the finding 
that 6-OHDA reduces DA efflux, though not significantly, from rDAT-LLCPK1 cells 
(Figures 6 & 7), and significantly form hDAT-LLCPK1 cells (Figure 8) is rather 
interesting and reveals a striking difference between the mechanisms by which 
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these two compounds operate. This 6-OHDA-reduced DA efflux effect was further 
blunted by BIM inhibition of PKC (Figure 9), though this may be due to unstimulated 
release being reduced by the same inhibitor (Figure 9). Though these compounds 
produced no change in transporter expression (Figure 13) or palmitoylation levels 
(Figure 14), 6-OHDA, interestingly, blunted basal and PMA-stimulated transporter 
phosphorylation (Figure 12). This may explain the attenuation of reverse DA 
transport by 6-OHDA, though the 5 minute exposure to the drug during the efflux 
protocol may not allow enough time for the reversal of transporter phosphorylation 
to occur as the phosphorylation (Figure 12) was assessed after a 30 min drug 
exposure. To our knowledge, this is the first time a DAT substrate has been 
demonstrated to blunt both DA efflux and DAT phosphorylation. MPP+ altered 
neither DAT phosphorylation (Figure 12), DAT expression (Figure 13), nor DAT 
palmitoylation (Figure 14). 
 As seen in Figures 2 and 3, pretreatment of DAT-expressing cells with the 
PD-inducing neurotoxic DAT substrates downregulated DAT-mediated DA uptake 
activity – MPP+ to a greater extent than 6-OHDA (Figures 4 & 5). These results are 
consistent with the general behavior of DAT function after exposure to its 
substrates for the time used in these experiments (30 min); that is to say, DAT-
conducted transport of substrate (DA, AMPH, or methamphetamine) across the 
plasma membrane reduces the capacity of the same DAT population to translocate 
subsequent substrate220,481–486. This effect, however, occurs after substrate 
exposure times greater than 1 min, before this point substrates rapidly recruit 
transporter copies from endosomal pools to the plasma membrane487, acutely 
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increasing DA uptake capacity. Depending on the study, the substrate-induced 
downregulation of DAT activity has been shown to be one484,488 or a 
combination483,486 of transporter internalization and PKC activity, and depends on 
substrate species482,485,489. Interestingly, substrate exposure induces this DAT 
uptake attenuation upon dorsal striatal DATs and not nucleus accumbens 
DATs481,483,485, suggesting a cellular environment sensitive to DAT substrates in 
dorsal striatal neurons and absent in accumbens neurons which responds to 
transporter activity or cytosolic substrate to shut down DAT function. These could 
be an outcome of divergent post-translational modification, endocytic, or 
antioxidant mechanisms. It may be one of these systems which responds 
differently to DAT or cytosolic chemistries instigated by 6-OHDA or MPP+ to 
produce their contrasting effects on DAT activity. Transporter surface population 
alterations need to be assessed to determine whether the observed toxin-induced 
DA uptake downregulation results from a loss of plasma membrane protein or 
other DAT-intrinsic or cellular environment factors. 
 Perhaps the most intriguing results from this study surround the DA efflux 
investigations and reveal further differences between the actions of 6-OHDA and 
MPP+ (Figures 6-11). MPP+ acts as a DA efflux enhancer while 6-OHDA is a DA 
efflux reducer. The efflux response to MPP+, like AMPH, was blunted after PKC 
inhibition though not abolished. This suggests that MPP+ and AMPH utilize PKC 
activity to prompt DAT-mediated DA efflux in a similar manner. That MPP+476,490,491 
and AMPH492,493 also act as substrates for the vesicular monoamine transporter 2 
(VMAT2)239,240 further supports these molecules sharing similar DA-efflux inducing 
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identities. These VMAT2 substrates empty vesicles of sequestered transmitter to 
elevate cytosolic DA concentration, a process associated with degeneration of the 
nigrostriatal DA tract494, perhaps by increasing the likelihood of DA-derivative 
reactive oxygen species toxicity and/or enhancing DAT-facilitated DA efflux 
causing a perturbed synaptic DA homeostasis. 6-OHDA reduction of carrier-
mediated reverse DA transport renders this compound unique amongst DAT 
substrates. The mechanism by which this occurs may involve oxidation damage to 
important protein actors to the efflux schema, or its direct modification of DAT 
which biases the transporter in an efflux-unfavorable conformation. PKC may be a 
target of 6-OHDA activity which may be the mechanism by which 6-OHDA 
attenuates basal and PKC-stimulated transporter phosphorylation, which, in turn, 
would ablate DA efflux.    
 The neurotoxic effects on the DAT phosphorylation (Figure 12) and 
palmitoylation (Figure 13) post-translational processes illuminated a potential 
mechanism by which one of the studied compounds may alter DA efflux. Increased 
transporter phosphorylation is classically identified with increased DA efflux 
capacity229, and, therefore, compounds which can reduce transporter 
phosphorylation, like 6-OHDA, can conceivably reduce transporter-mediated 
efflux. That MPP+ did not increase basal or PMA-stimulated DAT phosphorylation 
may be due to low stoichiometric abundance of the induced phosphorylation event 
which cannot be distinguished by the methodology used, especially in the PMA 
background. The BIM-induced reduction of MPP+-stimulated DA efflux may be a 
result of losing off target PKC and DAT interactors whose interplay is supported by 
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MPP+ action rather than a loss of direct MPP+-triggered DAT phosphorylation. 
Neither 6-OHDA nor MPP+ attenuated DAT palmitoylation which may be a result 
of insufficient toxin exposure time or DAT palmitoylation being insensitive to these 
compounds. As there is a reciprocal relationship between DAT phosphorylation 
and palmitoylation347, 6-OHDA may generate increased transporter acylation after 
longer drug incubation periods.  
 As stated previously, an anomalous DA efflux phenotype has been linked 
to patients diagnosed with ADHD380 and early onset PD256. This DA efflux event is 
now linked to disease etiology, drug rewarding and abuse properties226,495, and an 
additional potential mechanism by which PD can be induced after MPP+ exposure. 
DAT-mediated DA efflux does not only occur at perisynaptic DATs; indeed, 
dopaminergic neuronal dendrites form dendro-dendritic synapses in the substantia 
nigra496,497, and DA release at these synapses was proposed as a mechanism by 
which these neurons can self-inhibit498,499. A seminal study500 elucidated the 
mechanism by which this auto-inhibitory process occurs: DAT-mediated DA efflux 
at dendro-dendritic synapses. MPP+-produced DA efflux at this locus would likely 
induce the same auto-inhibitory effect on the nigro-striatal dopaminergic nerve 
cluster; perhaps stimulation of DA release by MPP+ contributes to this drug’s 
neurotoxic profile. This substantia nigra dendritic DA release is likewise elicited by 
AMPH treatment498,501. Taken further, both METH and AMPH use is associated 
with PD502–504, and a similar study observed an increased risk for PD amongst 
users of AMPH and METH but not cocaine505. These studies, along with the MPP+ 
DA efflux data presented herein, suggest induction of DA efflux at dendro-dendritic 
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synapses of the substantia nigra as a mechanism by which loss of the nigrostriatal 
DAergic tract, witnessed in PD, can be exacerbated. An antidote to this flux 
problem may be derived from uncovering the mechanisms by which 6-OHDA 
blunts DAT-mediated DA release, as one of them may reveal a novel therapeutic 
input point at which aberrant DA efflux-associated diseases can be alleviated. 
Perhaps this input point can remain DAT if a high-affinity DAT substrate can be 
synthesized which mimics the properties of 6-OHDA which enable it to dampen 
DAT-mediated DA efflux (conceivably, one such property is reducing DAT 
phosphorylation) without the properties which cause massive oxidative damage.   
Methods 
 Cell Culture 
 LLCPK1420 cells stably expressing WT or mutant rDATs were grown in 
Dulbecco’s Modified Eagle Medium (DMEM) containing 5% fetal bovine serum, 
100 µg/mL penicillin/streptomycin, and supplemented with 400 µg/mL of the 
selection reagent Geneticin (G418) for stably expressing cell lines. Cells were 
maintained in a humidified incubator with 5% CO2 at 37oC.   
 Generation of DAT-Expressing LLCPK1 Cells 
For generation of cell lines stably expressing WT hDAT or rDAT cDNA 
constructs421, LLCPK1 parental cells were seeded into 12-well plates and grown to 
~50% confluence. At this point the cells were transfected. X-tremGENE 
transfection reagent was mixed with plasmid DNA (1.4 µg of DNA/well of a 12-well 
plate) at a reagent:DNA ratio of 3:2 in OptiMEM for 20 min at ambient temperature 
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after which the transfection complex was added to each well and transfection 
proceeded for ~36 hours. The cells were then transferred to a culture flask to 
undergo selection of expressing cells via 800 µg/mL G418 treatment. After two 
subculture passages at this G418 concentration, the cells were collected, the 
plasma membranes were harvested, and expression of r or hDAT was analyzed 
by immunoblotting with the anti-DAT mouse monoclonal antibody MAb16. If the 
transfection was successful, the stably expressing rDAT cells were maintained in 
400 µg/mL of G418 for all subsequent uses. 
 SDS-PAGE and Western Blotting 
 DAT proteins and peptides were denatured in Laemmli sample buffer (SB: 
125 mM Tris-HCl, 20% glycerol, 4% SDS, 200 mM DTT, 0.005% bromophenol 
blue) and were electrophoretically resolved using 4-20% polyacrylamide gels 
alongside a ColorBurst protein standard. Proteins were then transferred to a 
transfer buffer (25 mM Tris-HCl, 192 mM Glycine, 0.1% SDS, 10% methanol) -
equilibrated polyvinylidene fluoride (PVDF) membrane after which blocking was 
performed with a 3% BSA/PBS buffer. Primary MAb16 antibody was diluted 
1:1,000 in the blocking solution and the blocked PVDF membrane was incubated 
in this antibody solution for 1 hour at ambient temperature. After five washes the 
membrane was incubated in alkaline phosphatase (AP)-linked anti-mouse IgG 
secondary antibody diluted to a 1:5,000 ratio in blocking buffer for 1 hour followed 
by 5 additional washes. 3 mL of Immun-Star™ AP substrate (Bio-Rad) was applied 
to the membrane and incubation proceeded for 5 min at ambient temperature. 
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Generated chemiluminescent Western blot band intensities were quantified using 
Quantity One® software (Bio-Rad).    
 Neurotoxin Dose-Response Assay on Inhibition of DA Uptake 
 WT rDAT LLCPK1 cells were seeded in 24-well assay plates and grown to 
~80% confluence. Immediately preceding the assay, serial dilutions of 6-OHDA 
(final reaction concentrations of 1 x 10-5, 1 x 10-4, 1 x 10-3, 1 x 10-2, and 3 x 10-2) 
and MPP+ (final reaction concentrations of 1 x 10-7, 1 x 10-6-, 1 x 10-5-, 1 x 10-4, and 
1 x 10-3) in 150 µL of Krebs Ringer/HEPES buffer (KRH, 25 mM HEPES, 125 mM 
NaCl, 2.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 5.6 mM glucose, 1.3 mM 
CaCl2) containing 25 µM DA. The cells were washed with 37oC KRH after which 
500 µL of 37oC KRH was added to each well. Assay plates were placed in a rocking 
water bath at 37oC. DA uptake was initiated by addition of 10 µL of the appropriate 
neurotoxin/DA mixture to each well at timed intervals. The uptake reaction 
proceeded for 8 minutes and was terminated by aspiration of the reaction mixture 
and 2 washes of each well with ice-cold KRH. The cells were solubilized with 250 
µL of Trition X-100 at ambient temperature for 30 minutes with gentle shaking. The 
solubilized cells were collected in scintillation vials to which 3 mL of scintillation 
fluid was added. Radioactivity was assayed by scintillation counting. The extent of 
DA uptake inhibition was relative to uptake control wells which received no 
neurotoxin inhibitor, and IC50 concentrations of each neurotoxin were determined 
by nonlinear regression analysis (one site competitive binding).  
 DA Uptake Downregulation Assay 
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 WT rDAT-LLCPK1 cells were seeded in 24-well assay plates and grown to 
~80% confluence. These cells were washed with 37°C KRH and subsequently 
pretreated with vehicle, 400 nM PMA, 20 µM DA, 20 µM 6-OHDA, or 20 µM MPP+ 
in 500 µL KRH at 37°C and 5% CO2 for 30 min. The cells were then rapidly washed 
with 4°C KRH three times prior to assay for DA uptake. DA uptake was induced by 
addition of 10 µL of the DA reaction mixture (Final concentration of DA was 3 µM) 
at timed intervals. DA uptake continued for 8 minutes and was terminated by 
removal of reaction buffer and well washout with 1 mL of ice-cold KRH. The cells 
were solubilized with 250 µL Trition X-100 for 30 minutes at ambient temperature 
and gentle rocking. Cell lysate was collected into scintillation vials and radioactive 
content was determined by scintillation counting. DA uptake downregulation is 
expressed as the percentage of DA uptake loss compared to untreated control 
cells. 
Neurotoxin Pre-Incubation DA Uptake Assay  
24-well plates grown to ~80%-90% confluence with LLCPK1 rDAT or hDAT 
cells were washed with 0.5 mL 37oC KRH buffer and resupplied with KRH buffer 
with or without 400 nM PMA, 20 µM DA, 20 µM 6-OHDA, or 20 µM MPP+ for 30 
min at 37oC and 5% CO2. These same concentrations were incubated in the 
presence of 100 µM cocaine for the DAT uptake control conditions, also for 30 min 
at 37oC and 5% CO2. After the substrate incubation, DA uptake was conducted for 
8 min at 37oC with 3 µM total DA containing 10 nM [3H]DA. Excess DA was rapidly 
washed out with KRH buffer and the cells were lysed by incubation with 250 µL 
1% Tx-100 for 20 min at ambient temperature. The lysates were collected and 
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analyzed for [3H] content by liquid scintillation counting. Neurotoxin uptake data 
are presented as % uptake control. The cocaine-treated conditions were compared 
to the cocaine control conditions.   
 Neurotoxin DA Efflux Assay 
Stably expressing WT hDAT or rDAT-expressing LLCPK1 cells were grown 
in 24-well assay plates to ~80% confluence. Cells were loaded via DA DAT-
mediated uptake of 3 µM DA containing 10 nM [3H]DA for 30 minutes in 37oC KRH. 
Extracellular DA was rapidly washed out 3 times with 4oC KRH on ice, and the 
assay plate was transferred back to the water bath and 37oC KRH efflux buffer 
with KRH alone, 10 µM AMPH, or the indicated neurotoxin concentration was 
rapidly added to avoid cell drying and rupture upon buffer addition. The efflux buffer 
was collected after five minutes and analyzed for radioactive content; one column 
of cell wells received no efflux buffer and was lysed by incubation with 1% Triton 
X-100 for 20 min at ambient temperature and served as the total internal [3H]DA 
control and was analyzed in parallel for [3H] content by liquid scintillation counting. 
The efflux values are expressed as a percent of the total intracellular [3H]DA. For 
the PKC inhibition DA efflux experiments, cells were incubated with 10 µM 
Bisindolylmaleimide (BIM) in KRH during the 30 min load portion of the experiment. 
Dopamine Transporter Phosphorylation Assay 
WT rDAT LLCPK1 cells were grown to 80% confluence in 6-well assay plates. 
Once desired confluence was achieved, cell medium was replaced with PO4-free 
medium and incubated for 1 hour at 37oC and 5% CO2. 10 µL of 32PO4-containing 
medium was then added to each well (final radioactivity concentration: 0.5 
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mCi/mL). This incubation proceeded for 2 hours after which 1mM of each 
neurotoxic compound was added for 30 minutes with or without the transporter 
phosphorylation-stimulating 200 nM PMA positive control. Cells were washed 
three times with ice-cold Buffer B (0.25 mM Sucrose, 10 mM triethanolamine, and 
pH was adjusted to 7.8 with 100 mM acetic acid), scraped, and collected in 
separate microfuge tubes. The collected cells were centrifuged at 2,000 xg for 5 
min at 4oC and supernatants were discarded. Cell lysis was produced by 
resuspension and nutation of pellet in 750 µL lysis buffer (10 mM triethanolamine 
pH 7.8, 2 mM ethylenediaminetetraacetic acid [EDTA], 150 mM NaCl, and 0.1% 
Triton X-100 containing 100 mM DTT and protease inhibitor cocktail) for 10 
minutes at 4oC. This was followed by centrifugation of samples at 4,000 x g for 5 
minutes. The supernatants were transferred to fresh microfuge tubes and 200 µL 
of 2% SDS (0.5% final concentration) was added and vortexed well. These 
samples were subjected to a final centrifugation at 20,000 x g for 30 minutes at 
4oC. 900 µL of the supernatant fraction was collected from which 25 µL was 
analyzed by Western blotting to ascertain DAT levels. Equal DAT protein from 
each sample (200 µL, or adjusted to 200 µL with lysis buffer) was isolated by 
immunoprecipitation with protein A cross-linked to the rDAT-reactive poly-16 
antibody in immunoprecipitation buffer (IPB, 50 mM Tris, 0.1% Triton X-100, pH 
8.0) for 2 hours at 4oC with nutation. The column was washed 4 times with IPB 
containing 0.1% SDS at ambient temperature and DAT was eluted with 35 µL of 
1x sample buffer. Samples were subjected to SDS-PAGE for 1 hour 45 minutes at 
150 V and 35 mA in a 4-20% polyacrylamide gradient gel. The gels were dried and 
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radioactive content was assessed by autoradiography. Autoradiography 
signatures were normalized to equal, immunoblotted DATs from each sample and 
data are presented as % basal DAT phosphorylation. 
Plasma Membrane Preparation 
WT rDAT-LLCPK1 cells were grown in 150 mm plates to ~80% confluence. 
400 nM PMA, 1 mM 6-OHDA, or 60 µM MPP+ in KRH or KRH alone was applied 
to two plates each for 1 hour at 37oC and 5% CO2. After treatment, cells were 
washed twice with Buffer B, scraped, and collected in Buffer B containing a 
protease inhibitor cocktail of 1 µM phenylmethylsulfonyl fluoride (PMSF) and 5 µM 
EDTA at 4oC. Cells were then pelleted via centrifugation at 3,000 x g for 5 min at 
4oC, supernatants were removed, and the cell pellets were suspended in Buffer C 
(0.25 M sucrose, 10 mM triethanolamine, 1 mM EDTA, and the pH was adjusted 
to 7.8 with 100 mM acetic acid) and subsequently homogenized using a Dounce 
homogenizer. Cellular debris and nuclei were cleared from the homogenates by 
centrifugation at 800 x g for 10 min. The post-nuclear supernatant was collected 
and centrifuged at 18,000 x g for 12 min, and the resulting plasma membrane pellet 
was suspended in sucrose phosphate (SP) buffer (10 mM dibasic sodium 
phosphate, 0.32 M sucrose, pH 7.4 with 1 µM PMSF and 5 µM EDTA).    
Acyl-Biotinyl Exchange 
This ABE method was adapted from Wan et al341 where detection of 
palmitoylated proteins are described in three steps: Free cysteine thiols are 
blocked; thioester linked palmitoyl groups are specifically removed by 
hydroxylamine (NH2OH); and the previously palmitoylated and now free sulfhydryl 
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groups are biotinylated. Plasma membranes isolated from control, PMA, or 
neurotoxin-treated WT rDAT LLCPK1 cells were solubilized in 250 µL of ABE lysis 
buffer (50 mM HEPES pH 7.0, 2% SDS (w/v), 1 mM EDTA) containing protease 
inhibitor and 20 mM methyl methanethiosulfonate (MMTS) to react with unbound 
Cys sulfhydryl moieties and incubated for one hour at ambient temperature. MMTS 
was removed by a 1 mL acetone precipitation and centrifugation at 18,000 x g for 
10 min. The pellet was dissolved in 250 µL 4SB ABE buffer (50 mM Tris, 5 mM 
EDTA, 4% SDS, pH 7.4) and remnant MMTS was removed by an additional 1 mL 
acetone precipitation and centrifugation. The pellet was then subjected to a further 
acetone wash. The pellet was suspended in 200 µL 4SB buffer and thioesterified 
palmitate molecules were specifically removed by hydroxylamine (NH2OH); The 
sample was split equally (100 µL) into negative control (800 µL, 50 mM Tris-
treated) and NH2OH-treated (1.4 mM) halves and incubated at ambient 
temperature for 30 min with end-over-end mixing. The free sulfhydryl groups were 
reacted with 100 µL (0.4 mM final concentration) of a sulfhydryl-specific 
biotinylating reagent, HPDP-biotin in the Tris or NH2OH mixtures. The now HPDP-
biotin-containing samples were incubated for 3 min in a 37oC water bath then at 
ambient temperature for 1 hour. Excess NH2OH and biotin reagents were removed 
by the 4:1 acetone to sample volume precipitation, centrifugation at 18,000 x g, 
supernatant aspiration, 250 µL 4SB pellet suspension, 1 mL acetone precipitation, 
centrifugation at 18,000 x g, supernatant aspiration, 1 mL acetone wash, 
centrifugation at 18,000 x g, and supernatant aspiration workflow. The final pellet 
was suspended in 75 µL ABE lysis buffer and 10 µL of this was set aside for total 
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DAT immunoblotting while 65 µL was added to 50 µL of a 50%  slurry of 
Neutravidin resin in 1500 µL Tris buffer to affinity purify the biotinylated proteins or 
peptides overnight at 4oC with nutation. Unbound peptides were washed away by 
three cycles of 8,000 x g centrifugation and 900 µL radioactive 
immunoprecipitation assay buffer (RIPA: 1% Tx-100, 1% sodium deoxycholate, 
0.1% SDS, 125 mM sodium phosphate, 150 mM NaCl, 2 mM EDTA, 50 mM NaF). 
Proteins and peptides were eluted from the final pellet by incubation in 2x Laemmli 
SB for 20 min at ambient temperature. Samples were then subjected to SDS-
PAGE, and immunoblotted with mouse anti-rDAT primary antibody (MAb16). 
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CHAPTER 4 
DISCUSSION 
Limitations of the Work Presented in this Dissertation 
Many of the data presented are from analysis of mutation of the putative 
palmitoylation sites. As such, the presented data may be a result of the amino acid 
substitution rather than loss of palmitoylation of that residue. 
The main drawback of the ABE method is that the assay is susceptible to 
capture of proteins which are modified through thioester bonds between Cys 
residues and modifying groups other than a fatty acid. If the protein of interest 
forms non S-palmitoylation thioester bonds it will be picked up as a false positive 
for S-palmitoylation by ABE. Examples of other post-translational modifications 
that form thioester bonds include S-acetylation, which is supported by surrounding 
basic residues like the situation with DAT Cys6, the phosphopantetheine prosthetic 
group’s sulfhydryl modifying an interacting protein’s Ser hydroxyl, and acyl-CoA 
substrates506–508. The ABE method is unable to detect multiple modification events 
on poly-palmitoylated proteins which the acyl-PEG exchange (APE) method is able 
to do by incorporation of maleimides of known Mr into the protein which can be 
visualized by multiple upward band shifts in a Western blot corresponding to the 
number of the protein’s acylation sites509. 
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The biochemical efflux assay used throughout this dissertation relies on 
expressed DAT to transport extracellularly-applied [3H]DA into the cell to supply 
the efflux-ready substrate pool. The act of transporting DA induces transporter 
downregulation481–485 which likely affects DA efflux capacity as well as AMPH 
interaction with DAT. Scintillation counting of the radiolabeled DA, though 
quantitative, does not represent a 1:1 ratio of counted DA to effluxed DA. This 
assay can only be performed on heterologous expression systems or immediately 
after tissue excision.  
The majority of experiments in this dissertation were performed on DAT-
expressing cells and ought to be confirmed in endogenous tissue. 
Future Studies 
The APE method should be optimized for endogenous rDAT to confirm the 
number of S-palmitoylation sites. This will be difficult as one needs a large Mr 
maleimide linker to produce distinguishable DAT bands as it produces a thick, ~80 
kDa Western blot signature. [3H]palmitic acid labeling of WT NDAT, Cys6Ala 
NDAT, and Cys90Ala rDAT could be performed to confirm that modification of 
Cys6 and Cys90 is actually a palmitoylation event as opposed to an alternative 
thioester-based modification. To assess the 2BP-induced and Cys mutant DAT 
conformational alterations, binding assays of the high affinity cocaine analog [3H]-
2β-carbomethoxy-3β-(4-fluorophenyl)tropane) can be implemented. The 
contribution of global palmitoylation (using 2BP) and the novel DAT palmitoylation 
sites to DAT downregulation can be analyzed by PMA treatment and DA uptake 
assays. The test if PIP2 and cholesterol-DAT interactions are supported by 
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palmitoylation events, PIP2 inhibition391 and cholesterol depletion156 can be used 
to see if forward or reverse transport process are affected by these conditions. 
Cys90Ala rDAT should be assessed by microscopy to determine if palmitoylation 
of this residue suppresses surface transporter levels and increases endosomal 
DAT content. All the experiments described in chapter 2 that can be applied to 
Cys6/90/580Ala rDAT should be carried out. Time course neurotoxin treatment 
should be implemented to assess whether 6-OHDA or MPP+ have any effect on 
DAT palmitoylation and surface transporter expression. DAT palmitoylation 
characteristic can be influenced to attempt to alleviate the anomalous DA efflux 
phenotype of Ala559Val and other DAT single nucleotide polymorphisms 
associated with disease.   
Summary Conclusions 
The first study strongly supports the existence of amino-terminal 
palmitoylation. It indicts the residues Cys6 and Cys90 as the potential 
palmitoylation sites in addition to Cys580. This study further concludes a Cys90 
acylation event may suppress surface transporter expression and this residue is 
important for maintaining DAT uptake Km for DA. Mutation of Cys6 to Ala 
decreases basal and AMPH-stimulated DA efflux, and global palmitoylation 
contributes to DA uptake stabilization and dampens DA efflux. Manipulation of DAT 
palmitoylation status may be an avenue of approach to finer pharmaceutical 
control over DAT activity.  
The second study concluded 6-OHDA is a DAT substrate which blunts both 
DA efflux and transporter phosphorylation, and MPP+ downregulates DA uptake 
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and strongly induces DA efflux. This study further implicates the DA efflux 
phenomenon as contributing to PD pathology256, and warns against the use of 
efflux-inducing DAT pharmacotherapies which predispose one to PD. 
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